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Muscular dystrophies are a clinically and genetically heterogeneous group of 
inherited disorders that cause progressive weakness and atrophy of muscles. 
They are divided into several subgroups based on the clinical and genetic 
findings. Mutations in dozens of different genes are known to cause the 
disorders, but the proportion of still unsolved cases in all subgroups remains 
substantial. The aims of this doctoral study were to identify unknown genetic 
defects in muscular dystrophy patients using Sanger sequencing and next-
generation sequencing methods, and to develop a targeted gene panel for 
routine diagnostic use. In the course of this study more than 30 muscular 
dystrophy families or sporadic patients obtained a molecular diagnosis. A 
majority of the identified mutations were located in TTN gene, encoding titin 
protein, which is a giant muscle protein having a central role in aspects of 
development, structure and function of the striated muscle. Muscle diseases 
caused by mutations in TTN are called titinopathies. 
Hereditary myopathy with early respiratory failure (HMERF) is an 
inherited muscle disease causing slowly progressive distal and proximal limb 
weakness with early respiratory failure and typically begins in the third to 
fifth decades of life. In this study 12 unrelated HMERF families from seven 
different countries were studied in order to reach a molecular diagnosis. 
Whole exome sequencing (WES) was performed on one French family and a 
novel missense mutation in TTN exon 343 was identified. The rest of the 
families were screened by Sanger sequencing and four other missense 
mutations in the same exon were identified. One of the mutations was 
previously reported, but the rest were novel. All but one of the mutations 
were dominant. One seemed to be recessive, since it did not always cause a 
disease in a heterozygous state. These findings considerable expanded the 
mutational spectrum of HMERF and highlighted the geographically wide 
occurrence of the disease as well as the role of TTN exon 343 as a mutational 
hotspot region. 
Tibial muscular dystrophy (TMD) is a relatively mild late adult-onset 
autosomal dominant distal myopathy characterized by weakness and atrophy 
especially in the tibialis anterior muscles of the lower leg. It is caused by 
mutations in the last exon, 363 (Mex6), of TTN. In a homozygous state the 
Finnish founder TMD mutation, FINmaj, causes a completely different 
disease, a severe childhood onset limb-girdle muscular dystrophy type 2J 
(LGMD2J). In this study patients having heterozygous TMD mutations, but 
more severe or atypical phenotypes were studied. Protein and RNA studies 
suggested possible additional mutations in TTN, which could account for the 
different clinical phenotype. Sanger sequencing revealed five patients having 
a frameshift mutation and one patient having a missense mutation in 
compound heterozygosity with the TMD mutation. In addition, one patient 
was homozygous for the previously reported Iberian TMD mutation. The 
patients having the FINmaj TMD mutation in combination with the 
 
 
frameshift mutation had an LGMD phenotype like the homozygous FINmaj 
patients. And the patients having the French Mex5 or Iberian TMD 
mutations in combination with the novel frameshift mutation had a more 
severe distal myopathy phenotype as well as the patient homozygous for the 
Iberian TMD mutation. The patient having the missense mutation in 
compound heterozygosity with the FINmaj TMD mutation had a completely 
new titinopathy phenotype differing from both TMD and LGMD. These 
results further expand the complexity of muscular dystrophies caused by 
TTN mutations and suggest that the coexistence of second mutations may 
constitute a more common general mechanism explaining phenotype 
variability. 
A targeted next-generation sequencing (NGS) gene panel, MyoCap, was 
developed in this study to provide a fast and cost-effective method to 
sequence 180 myopathy related genes simultaneously. The selected genes 
comprised 138 previously reported myopathy-causing genes and 42 novel 
genes, which could potentially cause muscle diseases. When compared to 
WES MyoCap provided a better read coverage with lower price and faster 
analytics for the targeted genes. The results were also reliable with high 
sensitivity and specificity. In this study altogether 65 myopathy patients were 
sequenced using the assay. Four of the patients served as mutation controls 
with previously identified mutations and 61 were research patients having 
undetermined mutations despite previous attempts trying to solve them. The 
causative mutation was totally or partly solved in 19/61 (31 %) patients. A 
majority of the solved patients had mutations in the TTN gene. Due to the 
huge size of TTN, the gene was not routinely sequenced before the NGS era, 
and novel findings in it were expected. 
The MyoCap gene panel was used to detect mutations also in six families 
with recessive distal myopathy. Altogether three novel TTN mutations in 
exons 362 (Mex5), 363 (Mex6) and 340 were identified in either homozygous 
state or in compound heterozygosity with an I-band or A-band nonsense or 
frameshift mutation. The novel mutations in Mex5 and Mex6 in compound 
heterozygosity with frameshift mutations caused similar more severe TMD 
phenotypes as the previously reported French Mex5 and Iberian TMD 
mutations when compound heterozygous with TTN frameshift mutations. In 
addition, one patient with a new distal myopathy phenotype had a novel 
missense mutation in TTN A-band exon 340 in compound heterozygosity 
with an A-band nonsense mutation. The results expanded the list of distal 
myopathies with a new category: juvenile or early adult onset recessive distal 
titinopathy. 
The MyoCap gene panel has proved its usefulness in detection of 
mutations and it has been implemented in the molecular diagnostics of 
myopathies. It is now the first method of choice for molecular genetic 
diagnostic of myopathy patients in Finland if no clear candidate gene can be 




Muscular dystrophies are inherited muscle disorders with a wide spectrum of 
phenotypes and genetic causes. The main characteristics are progressive 
weakness and wasting of muscles. The severity, age of onset, mode of 
inheritance and affected muscle groups vary greatly in different subtypes 
(Mercuri and Muntoni, 2013). Mutations in dozens of genes are known to 
cause these disorders, but since the genetic defect in many patients is still 
unsolved, the number of known causative genes will likely expand in the 
future. Many of the causative mutations are de novo and possibly present in 
only one affected patient. Resolving the genetic cause in such sporadic cases 
is difficult. In addition, small families with only few affected members are 
challenging with traditional gene mapping and Sanger sequencing 
approaches. Clinical, histopathological and Western blotting studies can give 
clues of the possible genetic cause, but if no clear candidate gene can be 
determined the exact molecular defect may remain unsolved. Identifying the 
causative mutations is important, since it enables optimal management of 
the disease. Identifying the causative genetic defect is the first step in 
understanding the pathomechanism of the disease and the first step towards 
therapeutic possibilities. Early therapy trials in muscular dystrophies are 
underway and without exact molecular diagnosis such trials are beyond reach 
for the patients (Jirka and Aartsma-Rus, 2015; Negroni et al., 2015). 
 
Titinopathies are muscle diseases that are caused by mutations in TTN. 
Mutations in the gene can cause muscular dystrophies, but also cardio-
myopathies or combinations of cardiac and skeletal muscle disorders. 
Titinopathies are an increasingly diverse group of muscle disorders ranging 
from mild distal muscular dystrophy to very severe congenital disorders 
leading to premature death (Chauveau et al., 2014b). TTN comprises 363 
exons and it encodes titin protein, which is the largest protein in human and 
nature (Bang et al., 2001). Titin is the major structural protein in the muscle 
sarcomere, providing the backbone scaffold and elasticity to the contractile 
filaments in the myofibrils, and it has key roles in muscle development and 
regulatory signaling functions (Fürst et al., 1989; Kontrogianni-
Konstantopoulos et al., 2009; Labeit and Kolmerer, 1995; Lange et al., 2005). 
Detecting mutations in TTN has been a challenge due its huge size and very 
laborious and expensive with conventional Sanger sequencing. 
 
During the recent years next-generation sequencing (NGS) has emerged as a 
revolutionary tool to discover genetic defects fast and cost-effectively 
(Koboldt et al., 2013). It has enabled the sequencing of the whole genome, 
exome or targeted genes in only one experiment. In disorders like muscular 
dystrophies it provides an efficient tool to overcome the challenges of clinical 
and genetic heterogeneity and the challenge of the extremely large muscle 
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genes. NGS methods enable identifying of mutations also in individual 
sporadic patients, which have been difficult or even impossible to solve 
previously (Shimojima et al., 2016). Gene panels for different disease groups 
have also been launched and are increasingly used in the clinical diagnostics 
as they provide a fast and reliable method to perform genetic testing (Lemke 
et al., 2012; Aparisi et al., 2014; Nikiforova et al., 2013). 
 
This doctoral study describes novel mutations identified in titinopathies and 
other muscular dystrophies. A few of the mutations were identified by 
conventional Sanger sequencing, and the rest by NGS. Whole exome 
sequencing (WES) was performed for one family and later a targeted gene 
panel, MyoCap, containing myopathy related genes was developed and used 
to detect mutations in 61 patients.  
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2 REVIEW OF THE LITERATURE 
2.1 HUMAN GENOME SEQUENCE AND VARIATION 
The DNA in the human genome is organized into 46 chromosomes in the 
chromatin of the cell nucleus and contains 22 autosome pairs and the sex 
chromosomes, XX for females and XY for males. One part of the genetic DNA 
material is embedded in the mitochondria in the cytoplasm of a cell. The 
human genome consists of 3 × 109 nucleotide base pairs of which more than 
99% are identical between individuals and the rest contain the genetic 
differences that makes each person unique. Sequencing of the human 
genome and establishment of the consensus reference sequence, the Human 
Genome Project, using DNA from anonymous donors, was essentially 
completed in 2003 and provided an initial exploration of the variation 
among human genomes (International Human Genome Sequencing 
Consortium, 2004). The human genome was estimated to contain 20 000 – 
25 000 protein coding genes. Approximately only 1.5 - 2 % of the human 
genome comprises protein coding regions, while the rest is non-coding 
including non-coding RNAs, regulatory DNA sequences, repeats, introns, 
pseudogenes and sequences with unknown function. Almost half of the 
human genome is composed of repetitive elements. More than 20% of the 
human genome comprises long interspersed nuclear elements (LINEs), 13% 
of short interspersed nuclear elements (SINEs), 8% of retrovirus like 
elements and 3% of inactive DNA transposons. In addition, approximately 
5% of the human genome consists of intrachromosomal or interchromosomal 
segmental duplications (Antonarakis, 2010). 
 
2.1.1 TYPES OF VARIATION 
Variations in the genome arise from errors during DNA replication or they 
can be spontaneous lesions introduced via exposure to toxic chemicals or 
radiation. Changes in the sequence, mutations, enable evolution, but they 
can also be harmful and cause diseases. It has been estimated that the 
average newborn acquires 50–100 new mutations at the diploid level (Lynch, 
2010). 
 
2.1.1.1 Single nucleotide variants 
A single nucleotide variant (SNV) is a substitution of a single nucleotide in 
the genome and the most common type of variation occurring at a rate of 
~1.0 × 10−8 per site per generation (Lynch, 2010). SNV can be a single 
nucleotide polymorphism (SNP), present in more than 1% of the general 
population or it can be a disease causing mutation. The National Center for 
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Biotechnology Information (NCBI) maintains the database for SNPs (dbSNP) 
including also short insertions and deletions. NCBI's ClinVar and the Human 
Gene Mutation Database (HGMD) contain information of variants that have 
been reported to have clinical significance. 
 
SNV can occur in the coding or non-coding region. A point mutation in a 
coding sequence is called missense if it changes an amino acid, synonymous 
or silent if it does not, and nonsense if it changes an amino acid to a stop 
codon. A point mutation can affect gene splicing if it occurs in the splice 
donor, acceptor or branch site and can result in exon skipping or intron 
retention or it can activate a cryptic splice site. A mutation in a gene 
promoter region can affect transcription factor binding. 
 
2.1.1.2 Deletions and insertions 
Deletions and insertions of a single or multiple (non-divisible by three) 
nucleotides cause a frameshift in the coding sequence. This leads to 
incorporation of incorrect amino acids and eventually to premature stop 
codon. It results in expression of a truncated protein, or it can trigger a 
nonsense-mediated mRNA decay (NMD). Deletions and insertions 
containing nucleotides divisible by three cause an in-frame deletion or 
insertion leading to loss or addition of amino acids in the sequence. Deletions 
and insertions are common causes of diseases because they often lead to 
seriously damaged or lost proteins. 
 
2.1.1.3 Short tandem repeats 
Short tandem repeats are variations containing a variable number of short 
sequence units, which are repeated several times e.g. CAGCAGCAGCAG. 
Tandem repeats with a unit size less than ten nucleotides are called 
microsatellites and with a unit size greater than or equal to ten nucleotides 
are called minisatellites. Tandem repeat sequences are prone to errors in 
replication and recombination, which can lead to changes in the number of 
repeated units (Gemayel et al., 2010). Trinucleotide repeat expansions have 
been reported to cause several human diseases including Huntington’s 
disease, fragile X syndrome and myotonic dystrophies type 1 (DM1) 
(Budworth and McMurray, 2013). 
 
2.1.1.4 Structural variants 
Structural variations (SVs) were originally defined as deletions, insertions or 
inversions greater than 1 kb in size (Feuk et al., 2006), but now as the 
sequencing of human genomes is becoming more common the spectrum of 
SVs has widened to include much smaller (~50 bp) variations (1000 
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Genomes Project Consortium et al., 2010). SVs include deletions, insertions, 
inversions, mobile element transpositions, translocations and copy number 
variations (CNVs). They are usually generated via non-allelic homologous 
recombinations of repetitive sequences, non-homologous end-joining or 
microhomology-mediated break-induced replications (Weckselblatt and 
Rudd, 2015). The Database of Genomic Variants contains structural variants 
identified in healthy control samples (MacDonald et al., 2014). 
 
CNVs are duplications (gains) or deletions (losses) of large genomic regions 
that are differentially represented in an individual compared to the reference. 
CNVs can change the number of exons or genes in the genome. For example 
DMD that encodes dystrophin protein has several known pathogenic CNVs 
including one or multiple exons (White and den Dunnen, 2006). Out-of-
frame mutations in DMD cause a severe Duchenne muscular dystrophy 
(DMD) with total loss of dystrophin, whereas in-frame mutations mostly 
cause a milder Becker muscular dystrophy (BMD) with altered or truncated 
dystrophin (Monaco et al., 1988). Inversions are segments of DNA that have 
reversed in orientation, and translocations are changes in position of 
chromosomal segments within the genome which do not change the total 
DNA content. Breakpoints generated by SVs can disrupt genes or alter gene 
expression. Inversions and translocations in DMD have also been identified 
in DMD patients (Tran et al., 2013; Worton et al., 1984). Mobile elements 
called retrotransposons can transcribe themselves into RNA and then 
reversely transcribe themselves back to DNA, which can be inserted at a new 
position in the genome. Fukuyama congenital muscular dystrophy is an 
autosomal recessive disorder caused by insertion of a transposon, SINE-
VNTR-Alu, in the 3' UTR of FKTN, which encodes fukutin (Kobayashi et al., 
1998). 
 
2.1.2 MODES OF INHERITANCE 
Monogenic Mendelian disorders can be inherited through autosomal 
dominant, autosomal recessive or X-linked manner. In the autosomal 
dominant inheritance a mutation on one heterozygous copy of the gene 
defect is sufficient to cause the disorder. A parent with an autosomal 
dominant disorder has a 50% risk of transmitting the disease to the child. 
Dominant mutations are often gain-of function mutations leading to proteins 
that have new deleterious functions, or they can be dominant negative 
mutations that interfere with the functions of the normal protein. Dominant 
mutations can also be loss-of-function mutations that lead to 
haploinsufficiency with insufficient levels of normal protein (Wilkie, 1994). 
 
In the autosomal recessive inheritance both copies of a gene must carry a 
mutation. Thus both parents need to carry at least one copy of the mutation 
in order to have an affected child and the risk is then 25%. Recessive 
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mutations are usually loss-of-function mutations leading to reduced or lost 
protein function, but the normal allele in the heterozygous carriers is able to 
produce enough protein to perform its normal functions. 
 
X-linked inheritance refers to diseases that are caused by mutations in genes 
on the X chromosome. X-linked diseases can be dominant or recessive, but 
the penetrance of disease can vary in females because they have two X 
chromosomes, and differences in the X chromosome inactivation can lead to 
varying degrees of expression of the different X alleles (Dobyns et al., 2004). 
Males have only one X chromosome, inherited from their mother, making 
them hemizygous for X chromosome genes. 
 
A mutation can also occur in the mitochondrial DNA, which is separate from 
the chromosomal DNA in the nucleus. All individuals inherit their 
mitochondrial DNA from their mother and therefore mitochondrial diseases 
have a maternal pattern of inheritance, but the number of mitochondria 
carrying the mutation can vary and thus the expression of mitochondrial 
disease can be variable (Taylor and Turnbull, 2005). 
 
A mutation can occur in either a germline or somatic cell, but only a germline 
mutation can be transmitted to the next generation, while somatic changes 
are only present in certain somatic cells of the body. A mosaic is an 
individual who has genetically different cells in the body. Mosaicism takes 
place when a mutation occurs in the early development and is then present in 
only part of the individual’s cells. Mosaicism may be seen in mildly affected 
parents of severely affected children (Samuels and Friedman, 2015). 
 
Atypical inheritance pattern can be caused by de novo mutations, for 
example, if a child has a dominant mutation but parents are healthy. Also 
reduced penetrance can cause atypical inheritance patterns. Penetrance 
means the frequency of people who are phenotypically affected when 
carrying a mutation. Reduced penetrance can be caused by modifier genes, 
epigenetic factors, environmental factors, influence of age or sex or effect of 
additional gene variants (Cooper et al., 2013). Inherited diseases can also be 
caused by multiple mutations in different genes and then no clear 
inheritance pattern can be seen. Polygenic diseases arise from mutations in 
multiple genes with cumulative effects. And multifactorial diseases may have 
multiple causative genes in combination with environmental factors. 
 
2.1.3 VARIANT DETECTION 
Different molecular and cytogenetic techniques have been applied during the 
last decades to identify genetic defects causing diseases. Previously the locus 
was often first mapped using genetic linkage analysis and microsatellite or 
SNP markers and then the linked region was Sanger sequenced in order to 
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detect the causative mutation. If a candidate gene was already known or 
suspected Sanger sequencing could be performed directly. To detect 
structural variations fluorescent in situ hybridization (FISH), comparative 
genomic hybridization (CGH) and multiplex ligation-dependent probe 
amplification (MLPA) was used (Katsanis and Katsanis, 2013). 
 
Currently the most widely used method to detect new mutations is NGS, 
which enables the sequencing of the whole genome, exome or targeted 
regions in only one experiment. Linkage analysis can be used together with 
NGS and they provide a powerful combination of tools for mutation detection 
(Ott et al., 2015). Detection of SVs using NGS can still be challenging and 
they may require use of other methods (Tattini et al., 2015). 
 
2.1.3.1 Linkage analysis 
Linkage analysis has been the primary tool for the genetic mapping of 
Mendelian disorders. It is based on the observation that genes and other 
genetic markers that reside physically close on a chromosome remain linked 
during meiosis. In meiosis homologous chromosomes exchange parts in a 
process called crossing-over or recombination. The further apart two genes 
on the same chromosome are, the more likely it is that a recombination 
between them will occur. Recombination fraction or recombination 
frequency (θ) between two loci is defined as the ratio of the number of 
recombined gametes to the total number of gametes produced. 
Recombination fraction is 0 < θ < 0.5, with θ = 0 indicating perfect linkage 
and θ = 0.5 meaning complete independence of the two loci. CentiMorgan 
(cM) is the distance between genes for which the recombination frequency is 
1%. The statistical estimate of whether two loci are likely to lie near each 
other on a chromosome and are therefore likely to be inherited together is 
called a LOD score, which is calculated as follows (Morton, 1955): 
 
    (1 – θ)N × θR 
LOD = log10  ───────── 
        0.5(N + R) 
 
θ = recombination fraction 
N = number of non-recombinant offspring 
R = number of recombinant offspring 
 
A LOD score of 3 or more is generally taken to indicate that the two loci are 
linked and are close to one another. It indicates 1000 to 1 odds that the 
linkage being observed did not occur by chance. A LOD score less than -2.0 is 
considered evidence to exclude linkage. The most commonly used markers 
for linkage analyses are microsatellites and SNPs (Kruglyak, 1997). 
Microsatellites are more informative, because they have a higher mutation 
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rate. SNPs on the other hand are more common and evenly distributed 
across the genome. Parametric linkage analysis requires specification of the 
inheritance model and allele frequency and penetrance parameters. It defines 
explicit relationship between phenotypic and genetic similarity. Parametric 
linkage analysis can be two-point or multipoint. Two-point analysis estimates 
the recombination fraction between each marker and disease locus. 
Multipoint analysis uses genotype information from several markers 
increasing the power of analysis (Teare and Barrett, 2005). 
 
2.1.3.2 Sanger sequencing 
Sanger sequencing is the conventional sequencing method used since 1977 
when it was developed by Frederick Sanger (Sanger et al., 1977). Sanger 
sequencing is still widely used in clinical diagnostics and research, but 
compared to NGS it has very low capacity and it is much more laborious and 
expensive if several genes need to be sequenced. In the diagnostics Sanger 
sequencing can still be used to detect mutations if a candidate gene is known. 
It is also used to confirm mutations found by NGS methods (Rehm, 2013). 
 
Sanger sequencing is based on the selective incorporation of chain-
terminating dideoxynucleoside triphosphates (ddNTPs) by DNA polymerase 
during in vitro DNA replication. The chain-termination method requires a 
single-stranded DNA template, primers, DNA polymerase, normal 
deoxynucleoside triphosphates (dNTPs) and modified ddNTPs, which 
terminate the DNA strand elongation. The ddNTPs were previously 
radioactively labeled for detection, but fluorescently labeled are used 
nowadays (Smith et al., 1986). Each of the four ddNTP chain terminators is 
labelled with fluorescent dyes that emit light at different wavelengths. 
Previously DNA fragments were size-separated using gel electrophoresis, but 
nowadays the sequencing is automated using DNA sequencers, which size-
separate strands by capillary electrophoresis, detect and record dye 
fluorescence and then output data as fluorescent peak trace chromatograms 
(Luckey et al., 1990). The read length in Sanger sequencing can reach 900 
nucleotides (Morozova and Marra, 2008). 
 
2.1.3.3 Next-generation sequencing 
NGS techniques started to emerge after the completion of the Human 
Genome Project (International Human Genome Sequencing Consortium, 
2004). The first NGS platform 454 was launched in 2005, followed by 
Genome Analyzer from Solexa and SOLiD from Agencourt the next year. 
Subsequently Roche acquired 454, Illumina acquired Solexa and Applied 
Biosystems/Life Technologies acquired Agencourt. Ion Torrent launched 
their platform 2010. All of the platforms have library preparation step that 
involve fragmenting genomic DNA and attaching specific adapter sequences. 
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And they all provide massive parallel sequencing via separated and amplified 
DNA templates in a flow cell, but they differ in configurations and in 
sequencing chemistry (Liu et al., 2012). 
 
The first DNA sequencing technology based on the sequencing by synthesis 
principle was pyrosequencing used in the 454 platform. In this technology 
DNA is fragmented and adaptors are attached. The DNA library is mixed 
with capture beads, polymerase chain reaction (PCR) reagents and an 
emulsion oil to create water droplets, each containing a single bead and a 
library fragment. Emulsion PCR is performed within this droplet and 
amplified DNA fragments are immobilised onto the bead. The beads are put 
in a plate comprised of wells which can accommodate only one capture bead. 
In each sequencing cycle one of the four possible nucleotides is washed over 
the plate and if the nucleotide is incorporated into the DNA template a 
pyrophosphate is released. Wells also contain smaller beads coated with 
adenosine triphosphate (ATP) sulfurylase and luciferase, which generate a 
chemiluminescent signal in the presence of pyrophosphate and the signal is 
detected by a camera (Margulies et al., 2005). 
 
The SOLiD platform utilizes sequencing-by-ligation principle, in which the 
mismatch sensitivity of a DNA ligase enzyme is used to determine the 
underlying sequence of the target DNA molecule. DNA is fragmented and 
adaptors are ligated to the ends. Emulsion PCR is used to immobilise and 
amplify the library fragment onto a paramagnetic bead, which is then 
immobilised on a glass slide. The ligation based sequencing is performed 
with fluorescently labeled universal octamer probes, which hybridize with the 
template and after detection of the fluorescence signal the dye is cleaved off 
(McKernan et al., 2009). 
 
Illumina is the most used of the platforms and it also utilizes the sequencing 
by synthesis method. First DNA is fragmented and adapters are ligated to the 
ends of the fragments. One of the adapters is hybridized on a flow cell which 
is coated with millions of primers complementary to the ligated adaptor 
sequences. Copies of each fragment are generated by bridge amplification in 
which free adaptor end anneals with a complementary primer creating 
clusters of the same molecule. Primer for the adapter is added and 
sequencing is performed using nucleotides that contain different fluorescent 
dyes, which are then detected by camera. A reversible terminator on every 
nucleotide prevents multiple additions in one round (Bentley et al., 2008). 
 
Ion Torrent uses semiconductor sequencing technology utilizing sequencing 
by synthesis method. First DNA is fragmented and adaptors are ligated to 
each end. The DNA library is amplified by emulsion PCR on capture beads. 
The beads are put onto a chip containing wells, which are able to 
accommodate a single coated bead. In each sequencing cycle one of the four 
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possible nucleotides is washed over the chip and incorporation of a 
nucleotide causes a proton release. The change in the pH within the well is 
detected by the ion sensor and converted to a digital signal (Rothberg et al., 
2011). 
 
A couple of sequencing platforms providing long read sequencing have also 
been launched: PacBio from Pacific Biosciences and MinION from Oxford 
Nanopore Technologies. They are platforms in which PCR is not needed 
before sequencing and the signal, fluorescent in PacBio and ionic current in 
MinION, is captured in real time as DNA strands are synthesized. PacBio 
provides single molecule sequencing technique with up to 40 000 
nucleotides read length utilizing a zero-mode waveguide (ZMW). In the 
system a single DNA polymerase enzyme is attached at the bottom of a ZMW 
with a single molecule of DNA as a template. Different fluorescent dyes are 
attached to each of the four nucleotides and when a nucleotide is 
incorporated by the DNA polymerase, the fluorescent tag is cleaved off and 
the detector detects the fluorescent signal. PacBio enables sequencing of only 
small genomes (Coupland et al., 2012). MinION device is about the size of a 
mobile phone and can be connected to a computer via a USB port. It 
sequences samples by measuring changes in ionic current when single-
stranded DNA molecules are translocated through nanopores. MinION is still 
under evaluation by the scientific community (Mikheyev and Tin, 2014). 
 
NGS enables sequencing of the whole human genome, exome or targeted 
regions in one experiment. In addition, transcriptome (RNA-seq), 
methylome (methyl-seq) or chromatin immunoprecipitation (ChIP-seq) 
sequencing is possible (Nguyen and Burnett, 2014). Whole genome 
sequencing (WGS) enables sequencing of the whole human genome fast and 
accurately in only few days. Limitations for its use have mainly been in the 
price as well as in challenges in the data analysis, interpretation and storage. 
Thus WES has been more widely used NGS application during the recent 
years (Gilissen et al., 2011). WES enables sequencing of all exons, which 
comprise ~2% of the human genome, but has been estimated to contain 
~85% of the disease-causing mutations (Majewski et al., 2011). Several 
different exome capture kits are available from different manufacturers. First 
chip-based exome capture kits were developed (Albert et al., 2007; Hodges et 
al., 2007), but since they required large amounts of input DNA they were 
quickly replaced by more efficient solution-based capture systems (Gnirke et 
al., 2009). 
 
Currently the major solution-based human exome enrichment systems are 
Agilent’s SureSelect Human All Exon, NimbleGen’s SeqCap EZ Exome 
Library, Illumina’s TruSeq Exome Enrichment, and Illumina’s Nextera 
Exome Enrichment. To capture genomic regions of interest using in-solution 
capture a pool of oligonucleotides called probes for regions of interest are 
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synthesized and biotinylated. The genomic DNA is fragmented, adapters are 
added to both ends and the DNA library is hybridized to the biotinylated 
probes. Streptavidin beads are used to pull down the complex of capture 
probes and DNA fragments and the DNA fragments are PCR-amplified. The 
major differences between the technologies correspond to the choice of the 
target regions, probe lengths, probe density, molecules used for capture and 
genome fragmentation method. Nextera uses transposomes for 
fragmentation, whereas others use ultrasonication. Agilent uses RNA 
molecules as probes, whereas other technologies use DNA. NimbleGen has 
the highest number of probes with overlapping probes and the highest probe 
density. Illumina covers the greatest portion of coding exons across RefSeq, 
Ensembl and CCDS databases (Chilamakuri et al., 2014). 
 
In addition to WES targeted gene panels are becoming widely used in 
diagnostic laboratories. Gene panels function in the similar manner as WES, 
but contain only selected genes relevant for the disorders of interest. 
Typically they contain a few to several hundred of genes. Many diagnostic 
laboratories have their own gene panels, but commercially available panels 
are also available for e.g. cancer, cardiac diseases and immune, neurological, 
neuromuscular, metabolic and sensory disorders (Rehm, 2013). The most 
widely used enrichment systems for targeted gene panels are hybridization 
based in-solution enrichments NimbleGen SeqCap EZ and Agilent SureSelect 
and amplicon based enrichment Agilent HaloPlex. The SeqCap and 
SureSelect enrichments for targeted genes are similar as the exome 
enrichment systems, but contain probes only for selected genes. The 
HaloPlex is an amplicon based enrichment system in which DNA is 
fragmented using eight restriction enzyme double digests. The probe library 
is then added and hybridized to the targeted fragments. The probes are 
designed to hybridize to both ends of the targeted DNA restriction fragment 
and guide them to form circular DNA molecules. The probes are biotinylated 
and the middle part of the probe contains a sequencing-specific motif. The 
circles are captured using streptavidin-coated beads, ligated to close the 
circles and PCR-amplified using barcoded primers (Bodi et al., 2013; 
Samorodnitsky et al., 2015). Also oligonucleotide microarrays have been used 
as solid-phase hybridization enrichment systems and microdroplet-based 
PCR, which contains a microfluidic device that creates aqueous droplets of 
forward- and reverse primers in an oil solution. The primer droplets are then 
merged with droplets containing fragmented genomic DNA and PCR 
reagents and thermal cycled in a single tube (Metzker, 2010). 
 
WES and targeted gene panels have some disadvantages compared to WGS 
due to the PCR-amplification, which causes problems especially in the GC-
rich regions showing low or absent coverage (Meienberg et al., 2015). Also 
CNVs are not easily detected due to the non-uniform depth of coverage and 
non-contiguous nature of the captured exons (Belkadi et al., 2015). The main 
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reasons of using WES and targeted gene panels over WGS have been lower 
price and smaller requirements of storage space and easier analysis. Lower 
cost enables sequencing of larger number of samples, which have made WES 
and targeted gene panels a better option especially in the diagnostics. The 
trend in research is however going forward to WGS as the human genome 
sequencing price $1000 per genome is becoming reality. Illumina has 
launched their HiSeq X Ten sequencer, which can sequence a human genome 
at 30X coverage or greater for less than $1000 (Watson, 2014). This means 
that WES does not have that strong price advantage anymore and since WGS 
has several advantages over WES it has started to become more and more 
used. WGS enables sequencing of variants also in the non-coding regions of 
the genome including introns, promoters and enhancers that are omitted in 
WES. In addition WGS has more uniform sequence coverage due to the lack 
of capture/hybridization and PCR steps. Both PCR-free and non-PCR-free 
WGS show lower GC bias compared to WES (Meienberg et al., 2015). The 
more uniform sequence coverage allows better detection of CNVs and other 
SVs (Belkadi et al., 2015). Also two to three times lower average read depth is 
sufficient in WGS compared to WES (Lelieveld et al., 2015). In both WGS and 
WES repetitive and homologous regions are difficult to align correctly to the 
human reference sequence due to the multiple identical locations in the 
genome. Longer read lengths and insert sizes could help to overcome this 
problem (Li and Freudenberg, 2014). 
 
After sequencing the genome, exome or targeted genes bioinformatics tools 
are needed to process the data to interpretable format. NGS data analysis 
starts with the alignment of the sequence reads to the human reference 
genome. One of the most used alignment software for this is Burrows-
Wheeler Aligner (BWA) (Li and Durbin, 2009). After alignment duplicates 
generated by PCR are removed and local realignment around indels is 
performed to reduce artifactual mismatches. Also base quality scores are 
recalibrated to more accurate. The recalibration tool attempts to correct for 
variation in quality with machine cycle and sequence context. The next step 
is a likelihood calculation for each possible genotype at each nucleotide, 
which can be a homozygote for the reference allele, a homozygote for the 
alternative allele or a heterozygote. This is based on quality scores and allele 
counts from the reads. Variant calling is performed to identify sites differing 
from the reference sequence. The Genome Analysis Toolkit (GATK) and 
SAMtools are softwares often used for variant calling (McKenna et al., 2010; 
DePristo et al., 2011; Li et al., 2009; Li, 2011). Variants differing from the 
reference sequence are annotated by adding information about the variant 
location (exonic, intronic, splice site, UTR or intergenic region) and type 
(synonymous, missense, insertion or deletion) as well as the gene name and 
changes at transcript and protein levels. Also the variant frequency in 
different databases and pathogenicity predictions using different 
conservation and prediction tools are useful information. Detection of 
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structural variants from NGS data is sometimes possible and based on 
discordant paired-end reads, split reads or depth of coverage (Nielsen et al., 
2011; Oliver et al., 2015; Abel and Duncavage, 2013). 
 
2.1.3.4 Mutation identification 
The interpretation of pathogenicity of detected variants can be challenging 
especially in the case of missense variants. The region of the mutation in the 
gene can give clues if other pathogenic mutations in the same gene or region 
have been reported. Also if the changed amino acid is very different in 
properties than the original e.g. if a hydrophobic amino acid is changed to a 
hydrophilic, a negatively charged to a positively charged or a small amino 
acid to a large amino acid, which can alter the structure and function of the 
protein. Sometimes it is possible to create a protein model and estimate 
weather the amino acid change can be harmful to the protein structure. It is 
also useful to check if the change is in a evolutionary conserved region with 
programs e.g. GERP, PhastCons or PhyloP or if the change is predicted to 
affect the protein structure or function using prediction tools e.g. MutPred, 
Condel, PolyPhen-2, SIFT or MutationTaster. 
 
Nonsense and frameshift mutations are usually pathogenic due to their 
deleterious effects on the protein, but often in a recessive manner. It has 
been estimated that human genomes typically contain ~100 loss-of-function 
variants and ~20 genes are completely inactivated (MacArthur et al., 2012). 
Variants located in the donor or acceptor splice sites can alter splicing, but 
other splicing mutations are more difficult to predict. NetGene2, Human 
Splicing Finder and GeneSplicer are programs that can be used to predict 
effects on splicing. The variants can also be further studied on RNA or 
protein levels. 
 
The variant frequency in the population is an important factor. Dominant 
mutations should have zero or almost zero frequency in the variant 
databases, whereas recessive mutations can have higher frequencies. In order 
to identify mutations in recessive disorders excluding variants with allele 
frequencies >1% is usually sufficient. Variant databases containing 
information about population frequencies include 1000 Genomes, Exome 
Sequencing Project (ESP) and Exome Aggregation Consortium (ExAC). NGS 
of parent-child trios is an efficient approach to identify de novo mutations. 
2.2 SKELETAL MUSCLE 
Skeletal muscles are voluntary muscles and responsible for mobility of the 
body. Skeletal muscle comprises 40% of body mass and is the most common 
of the three types of muscle tissue, the others being non-voluntary cardiac 
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and smooth muscles. Skeletal and cardiac muscles are striated whereas 
smooth muscles are non-striated. The most characteristic function of 
muscles is their ability to transform chemical energy into directed 
mechanical movement and force. The functional properties of muscle tissue, 
excitability, contractility, extensibility and elasticity, enable it to perform its 
mechanical function. The four important functions of the skeletal muscle 
tissue are to produce movement, maintain posture, stabilize joints and 
generate heat (Marieb and Hoehn, 2013). 
 
2.2.1 SKELETAL MUSCLE STRUCTURE 
The skeletal muscle cells, also known as myocytes or muscle fibers, are long 
tubular cells ranging from 10 to 100 μm in diameter and can be centimeters 
in length. They contain multiple nuclei since they arise from fusion of 
myoblasts, which are embryonic mesodermal cells. Each skeletal muscle fiber 
is supplied with a nerve ending that controls its activity. Skeletal muscles are 
attached to bones by collagen-rich fibers known as tendons (Figure 1A). The 
individual muscle is surrounded by a layer of connective tissue known as the 
epimysium. Groups of fibers within a muscle are arranged in bundles called 
fascicles and surrounded by another layer of connective tissue known as the 
perimysium. Endomysium is the connective tissue that surrounds each 
muscle fiber. The muscle fibers contain numbers of myofibrils, which run the 
entire length of the muscle fibers. Myofibrils are composed of myofilaments: 
myosin forming the thick and actin the thin filament, which slide along each 
other during muscle contraction. The myofibrils are built up of repeated end 
to end connected sarcomeres (Figure 1B), which are the basic functional 
units of muscle contraction and which provide the striated appearance of 
skeletal muscle. Titin is sometimes referred as the third filament in the 
sarcomere providing support to the contractile filaments and containing the 
molecular spring that restores each sarcomere and the whole muscle back to 
their resting length after contraction. The sarcomere is divided into four 
distinct sections called Z-disc, I-band, A-band and M-line (Marieb and 






Figure 1. A) Structure of skeletal muscle (based on the figure from Servier Medical Art, 
http://www.servier.com). B) A simplified schematic structure of the sarcomere. 
 
Skeletal muscle fibers are highly specialized cells and have special names for 
different cell organelles. A single muscle fiber is surrounded by a cell 
membrane called sarcolemma and the cytoplasm of a muscle fiber is known 
as sarcoplasm. The basal lamina associates closely with the sarcolemma 
providing protection. Satellite cells are the adult stem cells of skeletal muscle. 
They reside between the sarcolemma and the basal lamina and contribute to 
muscle growth, repair and regeneration. Mitochondria form a network 
throughout the muscle fiber and generate the energy needed for muscle 
actions when oxygen is available. The sarcoplasmic reticulum is a specialized 
type of endoplasmic reticulum that stores, releases and reuptakes the 
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calcium ions needed for muscle contraction (Figure 2). The calcium ions are 
stored in terminal cisternae, which are dilated end sacs of the sarcoplasmic 
reticulum. Between two terminal cisternae is a transverse tubule (T-tubule), 
which is a deep invagination of the sarcolemma and the pathway for action 
potential to signal the sarcoplasmic reticulum to release calcium. T-tubule 
and two cisternae form a complex called a triad (Marieb and Hoehn, 2013; 
Frontera and Ochala, 2015). 
 
 
Figure 2. The sarcoplasmic reticulum and T-tubules (based on the figure from Servier 
Medical Art, http://www.servier.com). 
 
Different skeletal muscle fiber types exist due to the diverse requirements of 
skeletal muscles in the body. The fibers are divided based on the speed of 
contraction that reflects how fast their myosin ATPases split ATP and based 
on the major pathways for forming ATP, which is either oxygen-using aerobic 
pathway or anaerobic glycolysis. The three main types of muscle fibers are: 
slow oxidative fibers (type 1), fast oxidative fibers (type 2A) and fast 
glycolytic fibers (type 2B). Skeletal muscles are a mixture of different fiber 
types and muscle fibers can also adapt to changing demands by changing size 
or fiber type composition (Marieb and Hoehn, 2013). 
 
2.2.2 MUSCLE CONTRACTION 
Muscle contraction occurs when an action potential travels down a motor 
neuron to the neuromuscular junction and releases acetylcholine, which 
binds receptors on the muscle sarcolemma and induces depolarization. The 
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action potential travels to the T-tubule causing voltage-dependent calcium 
ion release from the sarcoplasmic reticulum to the cytoplasm of the fiber. 
Calcium ions bind to troponin-tropomyosin complex located in the grooves 
of the actin filaments. This causes troponin to change conformation and 
tropomyosin slides out exposing the actin-myosin binding sites. Myosin 
interacts with actin by crossbridges and moves along the actin filament using 
energy from ATP hydrolysis. The muscle creates force and shortens. After the 
action potential has passed the calcium gates close and calcium pumps 
remove calcium from the cytoplasm back to the sarcoplasmic reticulum. The 
troponin returns to its normal shape and allows tropomyosin to cover the 
actin-myosin binding sites on the actin filament and the muscle relaxes 
(Marieb and Hoehn, 2013). 
 
2.2.3 MUSCLE PROTEINS 
Hundreds of different proteins have important roles in the muscle fiber. This 
chapter describes some of the most relevant proteins in the muscle 
sarcomere, sarcolemma and nucleus. 
 
2.2.3.1 Sarcomeric proteins 
2.2.3.1.1 Titin 
Titin is the largest known protein in human and encoded by TTN gene. The 
gene contains 363 exons and one alternative C-terminal exon, which is 
present in the novex-3 isoform. The total coding sequence is 114.4 kb and the 
protein-coding capacity is 38 138 amino acids with molecular weight of 4.2 
MDa (Bang et al., 2001). Titin has several described isoforms listed in the 
NCBI database, but none of them contains all the exons. The longest cardiac 
isoform, N2BA, contains 313 exons and is 104 301 nucleotides encoding 34 
350 amino acids and the longest known skeletal isoform, N2A, contains 312 
exons and is 101 518 nucleotides encoding 33 423 amino acids. The second 
last TTN exon 362 (Mex5), is differentially spliced in skeletal muscle 
(Kolmerer et al., 1996). 
 
One titin molecule spans half of the sarcomere from Z-disc to M-line and is 
present in all four sections of the sarcomere (Fürst et al., 1988). The titin C-
terminus is anchored to the M-line where two adjacent titin molecules from 
opposite Z-discs overlap (Obermann et al., 1996; Gregorio et al., 1998). Titin 
has several important functions in muscle. During myofibril assembly it 
functions as a molecular blueprint for sarcomere organization (Fürst et al., 
1989). Titin is also a scaffold protein containing numerous binding sites for 
other proteins throughout its length (Kontrogianni-Konstantopoulos et al., 
2009). It keeps other sarcomeric proteins in correct positions and maintains 
the sarcomeric structure during contraction and restores muscles back to 
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their resting length after contraction. The elastic spring element of titin is 
responsible for the passive elasticity of muscle and it is located in the 
differentially spliced I-band region (Labeit and Kolmerer, 1995). The sensory 
and signaling functions of titin are mainly located in the Z-disc, M-line and in 
the N2A and N2B elements of the I-band titin. Titin senses the mechanical 
status of the sarcomere and transmits information to signaling pathways that 
regulate muscle function via gene expression or protein turnover (Lange et 
al., 2005; Knöll et al., 2002; Miller et al., 2003). 
 
Titin is a highly modular protein, comprising immunoglobulin-like (Ig) and 
fibronectin type 3 -like (FN3) domains, but also unique sequences that are 
mainly present in the Z-disc, M-line and in the N2A and N2B elements of the 
I-band. The Z-disc consists of Z-repeats and unique sequences. A-band titin, 
which is the largest part of titin, contains repetitive super-repeats of Ig and 
FN3 domains. I-band titin contains tandem Ig domains and a repetitive 
PEVK region that is rich in proline (P), glutamate (E), valine (V) and lysine 
(K) residues and responsible for the elasticity of titin together with the Ig-
domains. I-band titin also contains two alternatively spliced elements, N2A 
and N2B, of which N2B is cardiac specific and N2A is present in skeletal 
isoforms and in the cardiac N2BA isoform. The exon coding for the 
alternative C-terminus of titin in the short novex-3-isoform is also located in 
the I-band. The function of this short isoform is not known, but it is present 
in both cardiac and skeletal muscles. Most of the alternatively spliced TTN 
exons are located in the I-band region. M-line titin contains Ig-domains (M1-
M10), unique sequences (is1-is7) and a kinase domain (Bang et al., 2001; 
Labeit and Kolmerer, 1995; Labeit et al., 1992; Linke, 2000) (Figure 3). 
 
 
Figure 3. Titin domains in the four sarcomeric regions. 
 






Figure 4. Sarcomeric proteins. 
 
2.2.3.1.2 Z-disc proteins 
The Z-disc separates one sarcomere from the next. The core of a Z-disc 
consists of anchored actin filaments from adjacent sarcomeres which are 
crosslinked by α-actinin molecules (Luther, 1991). The Z-discs vary in size, 
ranging between 30 and 50 nm in fast muscle and between 100 and 140 nm 
in slow muscle (Rowe, 1973; Luther et al., 2003). The amount of α-actinin 
links between actins depends on the fiber type with slow fibers having more 
links than fast fibers. Titin contains also several α-actinin binding sites on 
the differentially spliced Z-repeat region (Ohtsuka et al., 1997b; Ohtsuka et 
al., 1997a). The number of repeats correlates to the number of α-actinin 
molecules as wells as to the thickness of Z-disc (Gautel et al., 1996). Titin, 
actin and α-actinin form a ternary complex at the Z-disc (Young et al., 1998). 
 
The most N-terminal domains of titin interact with telethonin, also known as 
titin-cap, which connects the N-termini of two titin molecules (Gregorio et 
al., 1998). The Z-disc end of the actin filament is capped by a protein called 
CapZ which also binds to α-actinin and the C-terminus of nebulin, which is 
an actin-binding protein in the thin filament of the sarcomere (Papa et al., 
1999; Pappas et al., 2008). Myotilin is important for the stability of thin 
filaments during muscle contraction. It binds α-actinin and crosslinks actin 
filaments at Z-disc (Salmikangas et al., 2003). 
 
In addition to structural components, several proteins in the Z-disc are 
involved in mechanosensing and signaling. These include muscle LIM 
protein (MLP), also known as cysteine-rich protein 3 (CRP3), which in 
interaction with telethonin is thought to form a stress sensor complex (Knöll 
et al., 2002). Telethonin is also known to interact with calsarcin, which is 
also known as filamin, α-actinin, telethonin interacting Z-disc protein 
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(FATZ) or myozenin (MYOZ) (Frey and Olson, 2002). Calsarcin interacts 
with calcineurin, ZASP/LDB3 and myotilin (Frey and Olson, 2002; Gontier 
et al., 2005). Calcineurin plays important role in sensing and integrating 
intracellular calcium concentrations (Klee et al., 1979). ZASP interacts with 
α-actinin and may have role in myofibril turnover and load adaptation (Zhou 
et al., 1999). 
 
2.2.3.1.3 I-band proteins 
The major component of I-band is actin that forms the thin filaments of 
sarcomere together with nebulin, troponin complex (comprising troponin-I, 
troponin-C and troponin-T) and two strands of tropomyosins, which cover 
the active sites of actin and prevent myosin binding. Calcium ion binding to 
the troponin complex causes a conformation change and leads to 
tropomyosin moving away from the active site, which in turn enables actin-
myosin-interaction and muscle contraction (Farah and Reinach, 1995). In 
addition one molecule of nebulin spans the entire length of the thin filament. 
Nebulin is an actin-binding protein that stabilizes the thin filament (Witt et 
al., 2006). Actin proteins are monomers that polymerize to form thin 
filaments. Polymerization is reversible allowing actin filaments to be broken 
down when necessary. Cofilin 2 controls actin polymerization and 
depolymerization (Kremneva et al., 2014). 
 
Titin contains N2A, N2B and PEVK elements in the I-band region. The 
cardiac specific N2B element interacts with four and a half LIM domains 1 
(FHL1) and 2 (FHL2), which are transcriptional coactivators. FHL1 and 
mitogen activated protein kinase (MAPK) form a putative biomechanical 
strain sensor complex in N2B (Lange et al., 2002; Sheikh et al., 2008). The 
cardiac and skeletal muscle specific N2A element interacts with muscle 
ankyrin repeat proteins (MARPs), which are thought to shuttle to the nucleus 
in response to mechanical strain and act as negative regulators of gene 
expression (Miller et al., 2003). The PEVK segment associates with actin and 
binds calcium ions and presumably various SRC Homology 3 (SH3) domain-
containing proteins, which might also have a role in mechanosensitivity 
(Labeit et al., 2003; Ma and Wang, 2002). The titin I-band region contains 
also several binding sites for proteases. The elastic proximal-Ig region 
contains a binding site for calpain 1, N2A element for calpain 3 and Z-/I- 
region for metalloproteinase 2 (Coulis et al., 2008; Ojima et al., 2005; 
Duguez et al., 2006; Ali et al., 2010). In addition molecular chaperones have 
been shown to protect the spring region. A Smyd2-methyl-HSP90 complex 
stabilizes N2A and helps to maintain the sarcomeric I-band structure (Donlin 
et al., 2012). Another protective mechanism for I-band titin involves HSP27 
and αB-crystallin, which are translocated under stress to the I-band region 




2.2.3.1.4 A-band proteins 
The major component of A-band is myosin that forms the thick filament of 
sarcomeres. Myosin molecules comprise two heavy chains and four light 
chains and have three domains: head, neck and tail. The N-terminal parts of 
the heavy chains form the two myosin heads that contain actin- and ATP-
binding sites. The C-terminal tail provides an anchor that maintains the 
position of the heavy chain. The long tail forms the backbone of the thick 
filament and the heads protrude as crossbridges toward the thin filament. 
The neck domain binds essential and regulatory light chains (Ruppel and 
Spudich, 1996). Myosin interacts with myosin binding protein C (MyBP-C) 
and titin, which also binds MyBP-C (Offer et al., 1973; Murayama et al., 1989; 
Fürst et al., 1992). The interaction between myosin, titin and MyBP-C is 
believed to be responsible for maintaining the ordered arrangement of the 
sarcomere (Freiburg and Gautel, 1996). 
 
2.2.3.1.5 M-line proteins 
The myosin filaments are connected to each other via myomesin in the M-
line (Obermann et al., 1997). Also the C-termini of two titin molecules are 
connected via myomesin (Obermann et al., 1996). The proteins form a lattice 
including also obscurin and obscurin-like 1 (Fukuzawa et al., 2008; 
Sarparanta et al., 2010). The M-line is ideally placed to sensor mechanical 
strain as the M-line lattice is deformed only during active contraction. 
 
In the M-line titin interacts with muscle RING finger proteins 
MURF1/TRIM63 and MURF2/TRIM55 (Centner et al., 2001; Pizon et al., 
2002). MURF1 predominates in fast fibers and MURF2 in slow fibers. The 
MURF proteins can bind to serum response factor (SRF) in response to 
stress signals and mediate transcriptional repression of SRF target genes. 
The MURF proteins can also function as ubiquitin E3 ligases in ubiquitin-
mediated muscle protein turnover (Spencer et al., 2000; Perera et al., 2012). 
 
The M-line titin contains the titin protein kinase, which plays an important 
role in mechanotransduction. The kinase has been reported to be an inactive 
pseudokinase acting as a conformationally regulated scaffold that connects 
the ubiquitin ligases MURF1 and MURF2 and coordinates muscle-specific 
ubiquitination pathways and myofibril trophicity (Bogomolovas et al., 2014). 
The kinase also interacts with zinc-finger protein neighbor of BRCA1 gene 1 
(nbr1), which forms a signaling complex with sequestosome 1 (p62/SQSTM1) 
and MURF2. Nbr1 and p62/SQSTM1 are linked to autophagic protein 
turnover and muscle gene transcription, which lead to adaptation of muscle 
in response to changes in mechanical strain. Autophagy is an important 
protein degradation mechanism in muscle in addition to the ubiquitin-




The M-line titin also interacts with FHL2, which in turn binds to metabolic 
enzymes creatine kinase, phosphofructokinase and adenylate kinase and 
target them to the sarcomeric regions of high metabolic activity (Lange et al., 
2002). 
 
Calpain 3 is a skeletal muscle-specific calcium-activated cysteine protease, 
which specifically binds to titin in the M-line and I-band. The M-line binding 
site has a role in regulating the activity and stability of calpain 3. The protein 
is activated through autolysis within the active site and it lyses sarcomeric 
and sarcolemmal components when not trapped by titin (Sorimachi et al., 
1995). 
 
2.2.3.2 Sarcolemmal proteins 
The sarcolemma plays a central role in the skeletal muscle structure and 
function. It is directly involved in synaptic transmission and action potential 
propagation and has an essential structural role. A few important 
sarcolemmal proteins are depicted in Figure 5. 
 
 
Figure 5. Sarcolemmal proteins. 
 
The sarcolemma contains dystrophin-glycoprotein complex (DGC) that is 
composed of several transmembrane and peripheral components and it 
forms a link between the extracellular matrix and the cytoskeleton (Ervasti 
and Campbell, 1991). α- and β-dystroglycans are central proteins of the 
complex. α-dystroglycan is extracellular and binds laminin-α2 (merosin), 
which forms a structural part of the basal lamina (Shibuya et al., 2003).  β-
dystroglycan spans the sarcolemma and binds dystrophin inside the cell. 
Dystrophin is an important component that provides structural stability to 
the DGC. It binds the submembrane actin and intermediate filament 
cytoskeleton of the muscle fiber and completes the link between the 
cytoskeleton and the extracellular matrix (Ervasti and Campbell, 1993). The 
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absence of dystrophin permits excess calcium to penetrate the sarcolemma. 
In addition to dystroglycans and dystrophin, the core of the complex is also 
formed by four sarcoglycans (α, β, γ, and δ) and sarcospan (Crosbie et al., 
1997). They are thought to contribute to stabilization of the complex within 
the sarcolemma. The sarcoglycans are single transmembrane domain-
containing proteins and form a heterotetrameric complex. Sarcoglycans and 
dystroglycans are glycosylated on their extracellular domain and post-
translational processing is necessary for proper functioning of DGC (Michele 
and Campbell, 2003). Collagen VI is an extracellular matrix protein which 
forms a distinct microfibrillar network and has a critical role in maintaining 
skeletal muscle functional integrity (Sabatelli et al., 2001). 
 
The sarcolemmal proteins include also dysferlin, which is a transmembrane 
protein involved in calcium-mediated sarcolemma resealing (Bansal et al., 
2003). Caveolin 3 is an important component of caveolae, which participate 
in vesicular trafficing and signal transductin. Caveolin 3 inhibits dysferlin 
endocytosis (Tang et al., 1996). Anoctamin 5 is a putative cytoplasmic 
calcium-activated chloride channel. It is proposed to play a role in 
sarcolemmal maintenance and repair (Tsutsumi et al., 2004; Mizuta et al., 
2007; Bolduc et al., 2010). Desmin is a muscle-specific intermediate filament 
protein essential for the structural integrity and function of muscle. It 
connects the nuclear membrane, Z-disc and sarcolemma (Herrmann and 
Aebi, 2000). 
 
2.2.3.3 Nuclear proteins 
The nuclear envelope is an impermeable membrane barrier between the 
nucleus and the cytoplasm containing nuclear pore complexes that regulate 
transport of soluble macromolecules in and out of the nucleus. The nuclear 
envelope consists of the outer nuclear membrane that is continuous with the 
endoplasmic reticulum and a lumen, which is the inner nuclear membrane. 
The nuclear lamina is a dense fibrillar network inside the nucleus, which is 
thought to provide a framework for the nuclear envelope. It is mainly 
composed of lamin polymers and lamin-binding proteins that are embedded 
in the inner nuclear membrane. Lamin A and C are components of the 
nuclear lamina. They are reported to be involved in nuclear stability, 
chromatin structure and gene expression (Lammerding et al., 2006). Emerin 
is a single pass serine-rich transmembrane protein of the inner nuclear 
membrane that interacts with lamins A and C and mediates membrane 
anchorage to the cytoskeleton (Sakaki et al., 2001). SUN proteins are 
predicted to regulate nuclear envelope spacing. They are located in the inner 
nuclear membrane and they bind nesprin proteins in the outer nuclear 
membrane (Cain and Starr, 2015). Nesprin 1 and 2 are outer nuclear 
membrane proteins that link the nucleus to the actin cytoskeleton and are 
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critical for nuclear positioning and anchorage (Zhang et al., 2007). Some 
important nuclear proteins are depicted in Figure 6. 
 
 
Figure 6. Nuclear proteins. 
2.3 MYOPATHIES 
Myopathies refer to diseases that are caused by dysfunction or loss of muscle 
fibers in contrast to neurogenic muscle weakness secondarily caused by 
disorders of the nervous system. Myopathies can result in weakness and 
wasting of muscles, myalgias, cramps, muscle breakdown and contractures. 
Acquired myopathies are caused by external factors and can be due to 
metabolic derangements, toxic exposures, drugs, infections or autoimmune 
dysfunction causing inflammation in the muscle. Most myopathies are 
inherited and they have been divided into several subgroups. Muscular 
dystrophies are genetic myopathies that cause progressive loss of muscle 
tissue. Channelopathies are characterized by delayed relaxation after muscle 
contraction causing muscle stiffness and pain or episodes of flaccid muscle 
paralysis. They are caused by mutations in muscle ion channels that lead to 
increase or decrease in muscle membrane excitability. Mitochondrial 
myopathies may by isolated disorders of the muscle and they are frequently 
combined with dysfunction in multiple organ systems mediated by 
dysfunction of the mitochondrial respiratory chain proteins. Metabolic 
myopathies are caused by specific enzymatic defects that lead to restricted 
muscle energy metabolism and result in skeletal muscle dysfunction. 
Congenital myopathies are present from birth and include a number of 
diseases grouped by histopathology findings such as central core disease, 
congenital myopathy with fiber-type disproportion, multiminicore disease, 
myotubular (centronuclear) myopathy and nemaline myopathy. They are 
usually non-progressive and cause reduced contractility leading to muscle 




2.3.1 MUSCULAR DYSTROPHIES 
Muscular dystrophies are a subgroup of genetic myopathies characterized by 
progressive loss of muscle tissue leading to weakness and atrophy of muscles. 
Histopathologically the affected muscles show dystrophic changes including 
fiber necrosis and regeneration combined with replacement of muscle fibers 
by adipose or connective tissue (Costanza and Moggio, 2010). Clinically and 
genetically muscular dystrophies are a very heterogeneous group of 
disorders. The age of onset can vary from congenital to late adulthood 
depending on the disorder. Also the affected muscle groups vary considerably 
and in some disorders also the respiratory and cardiac muscles can be 
severely affected. Muscular dystrophies have been divided into several 
subgroups based on the clinical distribution of the muscle weakness and 
inheritance pattern before the genetic etiology was known (Mercuri and 
Muntoni, 2013). 
 
Muscular dystrophies are known to be caused by mutations in dozens of 
different genes and the number is likely to grow as novel mutations are 
identified (Kaplan and Hamroun, 2014). The heterogeneity of the disorders 
cause diagnostic difficulties because similar phenotypes can be caused by 
mutations in several alternative genes and also different mutations in one 
gene can cause different phenotypes. Muscular dystrophies can be inherited 
in autosomal dominant, autosomal recessive or X-linked manner depending 
on the disorder and many patients have de novo mutations. The prevalence 
for all muscular dystrophies is between 19.8 and 25.1 per 100 000 person-
years with the most common types being DM1 (0.5-18.1 per 100 000), 
facioscapulohumeral muscular dystrophy (FSHD) (3.2-4.6 per 100 000) and 
DMD (1.7-4.2 per 100 000) (Theadom et al., 2014). However, due to founder 
mutations the frequencies vary considerably in different populations and the 
corresponding numbers for Finland are very different: the most common is 
tibial muscular dystrophy (TMD) with prevalence of 20/100 000 and the 
prevalence of DM1 is 12/100 000 based on clinical data. In Finland DM2 is 
likely as common as DM1 (Udd, 2007). 
 
2.3.1.1 Congenital muscular dystrophies 
Congenital muscular dystrophies (CMD) are present at birth or begin at early 
infancy showing hypotonia and generalized weakness. Features of CMD 
include decreased motor abilities and delay or arrest of motor milestones. 
The patients often have joint contractures, scoliosis, feeding difficulties and 
respiratory insufficiency and in some subtypes the cardiac muscle, central 
nervous system or eyes can be involved. Some forms of CMD cause also 
mental retardation. The progression of CMD varies between subtypes and the 
disease may lead to death already in childhood. Several causative genes are 
known and CMDs have been divided into several subgroups (Table 1). The 
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most common CMDs are laminin-α2 deficiency, Ullrich congenital muscular 
dystrophy, fukutin-related proteinopathy, glycosylation disorders of α-
dystroglycan (dystroglycanopathies), SEPN1-related rigid spine syndrome 
and LMNA-related CMD. Intellectual disability, structural brain or eye 
abnormalities and seizures are found almost exclusively in the 
dystroglycanopathies, while white matter abnormalities without major 
cognitive involvement are present in the laminin α2-deficient subtype. 
Majority of the CMD mutations are recessive, but mutations in COL6A1 and 
COL6A2 can be dominant or recessive and LMNA mutations have been 
autosomal dominant de novo mutations (Bertini et al., 2011). 
 
Table 1. CMD subtypes and causative genes. 
Subtype Gene Protein 
Laminin alpha-2 deficiency 
(MDC1A) 
LAMA2 Laminin-α2 (Merosin) 
Collagen VI-deficient CMD/ 
Ullrich CMD/ Bethlem CMD 
COL6A1 Collagen VI 
COL6A2 Collagen VI 
COL6A3 Collagen VI 
Dystroglycanopathies POMT1 Protein-O-mannosyltransferase 1 
POMT2 Protein-O-mannosyltransferase 2 
FKTN Fukutin 
FKRP Fukutin-related protein 
LARGE Large 
POMGNT1 Protein O-linked mannose N-
acetylglucosaminyltransferase 1 (β1,2-) 
POMGNT2 Protein O-linked mannose N-
acetylglucosaminyltransferase 2 (β1,4-) 
ISPD Isoprenoid synthase domain-containing 
protein 
DAG1 Dystroglycan 
TMEM5 Transmembrane protein 5 
B3GALNT2 β1,3-N-acetylgalactosaminyltransferase 2 
GMPPB GDP-mannose pyrophosphorylase B 
POMK Protein-O-mannose kinase 
SEPN1-related myopathy/ rigid 
spine syndrome 
SEPN1 Selenoprotein N 
LMNA-related CMD (L-CMD) LMNA Lamin A/C 
 
2.3.1.2 Duchenne and Becker muscular dystrophies 
DMD and BMD, dystrophinopathies, are recessive X-linked disorders caused 
by mutations in DMD that encodes the dystrophin protein. Since the 
disorders are X-linked, majority of the patients are males, but milder disease 
may occur in female carriers. In the severe DMD dystrophin is completely 
absent and in the less severe BMD it is present in either a mutated or a 
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truncated form (Le Rumeur, 2015). The DMD gene is the largest gene in 
human, comprising 2.4 Mb and containing 79 exons. However, the longest 
transcript is only 14 kb, because the introns of the gene are very large. Of the 
reported mutations 65% are deletions of one or multiple exons, 10% are 
duplications of exons and 15% are point mutations (Flanigan et al., 2009; 
Tuffery-Giraud et al., 2009). Out-of-frame mutations lead to the severe DMD 
and in-frame mutations mostly to the less severe BMD (Monaco et al., 1988). 
 
DMD boys begin to show signs of proximal muscle weakness as early as 2-3 
years of age, with problems in walking and climbing stairs. They are never 
able to run and become wheelchair bound before the age of 12. A third of the 
boys also have a non-progressive mental retardation. The disease 
progressively weakens all the skeletal muscles in the limb and trunk, and 
later also respiratory and cardiac muscles. Respiratory and cardiac 
impairments progress and previously patients died around the age of 20. 
With current medical management the mean survival is around 40 years. 
BMD is a much milder version of DMD. The onset is usually in the teens or 
early adulthood and the progression is slower, but cardiomyopathy can be 
very severe (Le Rumeur, 2015). 
 
2.3.1.3 Emery-Dreifuss muscular dystrophies 
Emery-Dreifuss muscular dystrophy (EDMD), also known as 
humeroperoneal muscular dystrophy, causes a distinct muscle atrophy 
pattern with a humeroperoneal distribution and joint contractures. The 
muscle involvement of the upper extremities is predominantly proximal, 
while the weakness and wasting in the lower limbs is mostly distal. Weakness 
later extends to the scapular and pelvic limb-girdle muscles, but the course is 
slowly progressive. The onset of the disease is usually in the mid-childhood 
or the second decade. EDMD can be a severe disease due to the cardiac 
involvement that usually arises after the second decade and may lead to 
sudden death (Puckelwartz and McNally, 2011). 
 
Reported genes causing EDMD include EMD and LMNA, which encode the 
proteins emerin and lamin A and C in the nuclear lamina (Bione et al., 1994; 
Bonne et al., 1999). Mutations in FHL1 encoding FHL1 have also been 
reported (Gueneau et al., 2009). EMD mutations are X-linked recessive and 
FHL1 mutations X-linked dominant, while LMNA mutations can either be 
dominant or recessive. Dominant mutations have also been reported in 
SYNE1 and SYNE2 encoding nesprin 1 and nesprin 2, which connect nuclei to 
the cytoskeleton (Zhang et al., 2007; Puckelwartz et al., 2010). Recently 
reported recessive mutations in TTN cause an EDMD-like phenotype without 




2.3.1.4 Limb-girdle muscular dystrophies 
Limb-girdle muscular dystrophies (LGMD) are characterized by weakness in 
the proximal muscles around hip and shoulder girdles. To date 30 causative 
genes have been identified, of which seven are autosomal dominant and 23 
are autosomal recessive (Table 2). The autosomal dominant LGMD1 forms 
cause less than 10% of the LGMDs and they usually have adult-onset and 
milder phenotype, except LGMD1B and severe forms of LGMD1D (Mercuri et 
al., 2004; Palmio et al., 2015). The autosomal recessive LGMD2 forms are 
more common and range from very severe to mild. Many of them have a 
childhood or early adulthood onset (Nigro and Savarese, 2014). 
 
Table 2. Known LGMD genes and the proteins they encode. The LGMD1 forms are 
dominant and the LGMD2 forms recessive. 
Disorder Gene Protein 
LGMD1A MYOT Myotilin 
LGMD1B LMNA Lamin A/C 
LGMD1C CAV3 Caveolin 3 
LGMD1D DNAJB6 DnaJ/Hsp40 homolog, Subfamily B, member 6 
LGMD1E DES Desmin 
LGMD1F TNPO3 Transportin 3 
LGMD1G HNRPDL Heterogeneous nuclear ribonucleoprotein D-like protein 
LGMD2A CAPN3 Calpain 3 
LGMD2B DYSF Dysferlin 
LGMD2C SGCG γ-Sarcoglycan 
LGMD2D SGCA α-Sarcoglycan 
LGMD2E SGCB β-Sarcoglycan 
LGMD2F SGCD δ-Sarcoglycan 
LGMD2G TCAP Telethonin 
LGMD2H TRIM32 Tripartite motif containing 32 
LGMD2I FKRP Fukutin related protein 
LGMD2J TTN Titin 
LGMD2K POMT1 Protein-O-mannosyl transferase 1 
LGMD2L ANO5 Anoctamin 5 
LGMD2M FKTN Fukutin 
LGMD2N POMT2 Protein-O-mannosyl transferase 2 
LGMD2O POMGNT1 Protein O-linked mannose beta1,2-Nacetylglucosaminyl 
transferase 
LGMD2P DAG1 Dystroglycan 
LGMD2Q PLEC1 Plectin 
LGMD2R DES Desmin 
LGMD2S TRAPPC11 Transport protein particle complex 11 
LGMD2T GMPPB GDP-mannose pyrophosphorylase B 
LGMD2U ISPD Isoprenoid synthase domain containing 
LGMD2V GAA Alpha-1,4-glucosidase 




2.3.1.5 Distal muscular dystrophies 
Distal muscular dystrophies show progressive weakness and atrophy 
preferentially in the distal muscles of limbs used for movements including 
hands, fingers, ankles and toes. Muscle pathology shows myopathic and 
dystrophic changes depending on the site of muscle biopsy, and frequently 
rimmed vacuoles and/or myofibrillar pathology. Around 20 genetically 
distinct distal muscular dystrophies, historically called distal myopathies, are 
known to date (Table 3). The inheritance can be dominant or recessive and 
the age of onset can vary from infancy to late adulthood depending on the 
disorder. Miyoshy, Nonaka and Laing distal myopathies, KLHL9-myopathy, 
ABD-distal filaminopathy and distal nebulin myopathy are early onset 
disorders beginning in infancy, childhood or teens, but the rest of the 
disorders begin later in life. Many of the disease genes encode sarcomeric 
proteins. Distal myofibrillar myopathies include desminopathy, αB-
crystallinopathy, myotilinopathy and zaspopathy. The proteins associated 
with myofibrillar myopathy are located in the sarcomeric Z-disc and they 
form protein aggregates when mutated and lead to disintegration of the 
sarcomeric filament structure of the myofibrils (Udd, 2014). 
 
Table 3. Distal muscular dystrophies with identified gene defect. DM = distal myopathies, 
MM = Myofibrillar myopathies with distal phenotype. 
 Disorder Mode Gene Protein 
DM Miyoshi myopathy AR DYSF Dysferlin 
Nonaka myopathy AR GNE Glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine 
kinase 
Laing myopathy AD MYH7 Myosin, heavy chain 7, cardiac 
muscle, beta 
Tibial muscular dystrophy 
(Udd myopathy) 
AD TTN Titin 
Welander distal myopathy AD TIA1 TIA1 cytotoxic granule-associated 
RNA binding protein 
Vocal cord and pharyngeal 
distal myopathy 
AD MATR3 Matrin 3 
Distal ABD-filaminopathy AD FLNC Filamin C 
Distal caveolinopathy AD CAV3 Caveolin 3 
Distal VCP-myopathy AD VCP Valosin containing protein 
Distal KLHL9-myopathy AD KLHL9 Kelch like family member 9 
Distal anoctaminopathy AR ANO5 Anoctamin 5 
Distal nebulin myopathy AR NEB Nebulin 
Distal DNAJB6-myopathy AD DNAJB6 DnaJ/Hsp40 homolog, Subfamily 
B, member 6 
Distal ADSSL1-myopathy AR ADSSL1 Adenylosuccinate synthase like 1 
MM Desminopathy AD DES Desmin 
αB-crystallinopathy AD CRYAB αB-crystallin 
Myotilinopathy AD MYOT Myotilin 




2.3.1.6 Facioscapulohumeral muscular dystrophies 
FSHDs are divided into two types, FSHD1 and FSHD2, based on the type and 
effect of the mutation. Both types show asymmetric and progressive muscle 
weakness affecting initially the face, shoulders, and arms followed by the 
distal then proximal lower extremities. Symptoms typically develop during 
the teenage years, but they can begin at any age from infancy to later 
adulthood. The autosomal dominant FSHD1 is more common (~95%) and it 
is caused by chromatin relaxation induced by pathogenic contraction of a 
macrosatellite repeat D4Z4, located on the 4q subtelomere, and leading to 
pathogenic expression of DUX4. FSHD1 patients have one to ten D4Z4 
repeat units, while normal alleles have 11 to 100 repeat units. The D4Z4-
contraction alone is not pathogenic. Close to the last D4Z4 repeat unit is a 
polymorphic site with two allelic variants: 4qA and 4qB. The 4qA is in cis 
with a functional polyadenylation consensus site and only contractions on 
4qA alleles are pathogenic, because DUX4 transcripts originating from the 
4qA allele can be polyadenylated and translated into protein. DUX4 is a 
retrogene encoding double homeobox 4 (DUX4). It is a germline 
transcription factor that is normally repressed in somatic cells most probably 
by a mechanism of repeat-mediated heterochromatin formation. DUX4 in a 
muscle induces apoptosis and inflammation. FSHD2 is a digenic disease 
caused by heterozygous mutations in the SMCHD1 encoding structural 
maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1), 
which is an essential protein for chromatin condensation. Mutations in this 
gene lead to chromatin relaxation of the D4Z4 locus. In addition the patients 
have the 4qA allele in order to express stable DUX4 transcripts. Patients 
having both D4Z4 contraction and SMCHD1 mutations have also been found 
and they show a more severe clinical phenotype (Sacconi et al., 2015). 
 
2.3.1.7 Oculopharyngeal muscular dystrophies 
Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is a late-
onset muscle disease beginning in the fifth or sixth decade with progressive 
weakness and atrophy in the muscles of eyelids, face, and throat. Later also 
proximal skeletal muscles become affected (Ruegg et al., 2005). Specific 
histological hallmarks of OPMD are cytoplasmic rimmed vacuoles and 
intranuclear inclusions on muscle biopsy. To date only mutations in PABPN1 
have been reported to cause the disorder. The vast majority of the mutations 
are dominant trinucleotide repeat expansions (Brais et al., 1998). PABPN1 
encodes polyadenylate-binding protein nuclear 1 (PABPN1), which plays key 
roles in post-transcriptional processing of RNA controlling the poly(A) tail 
length. It is not known why mutations in a ubiquitously expressed gene lead 




2.3.1.8 Myotonic muscular dystrophies 
Myotonic muscular dystrophies are autosomal dominant disorders 
characterized by progressive muscle weakness and myotonia, inability to 
relax muscles. There are two major types of myotonic dystrophy, DM1 and 
DM2, which have distinct but overlapping symptoms. DM1 causes muscle 
wasting and weakness initially in the hands and feet and later in the head and 
neck, ending up with generalized weakness with dysphagia and respiratory 
failure. DMs are multiorgan disorders with heart conduction defects, 
cataracts and gastrointestinal, brain and endocrinological abnormalities. 
DM1 occurs in four different clinical phenotypes: congenital, childhood 
onset, classic adult onset, and mild late onset forms. DM2 is less severe than 
DM1 and without congenital or childhood onset forms and does not cause 
clinically relevant brain dysfunction. Primarily affected muscles in DM2 are 
proximal lower limb muscles and the disease onset is from the fourth to the 
eighth decade. Myotonia is usually mild or absent, but muscle pain can be 
disabling (Udd and Krahe, 2012). 
 
DM1 is caused by trinucleotide (CTG) repeat expansion in the 3′UTR of 
DMPK encoding dystrophia myotonica protein kinase (Brook et al., 1992). 
Normal alleles have 5-34 CTG repeats and disease alleles have >50 CTG 
repeats with considerable anticipation due to instability of the repeat tract: 
increase of repeat size in consecutive generations. A hallmark of molecular 
pathology in DM1 is the accumulation of CUG-expanded mRNA in distinct 
nuclear aggregates that sequester RNA-binding proteins (Ho et al., 2005; 
Jones et al., 2011). DM2 is caused by a tetranucleotide (CCTG) repeat 
expansion in the first intron of CNBP encoding CCHC-type zinc finger 
nucleic acid binding protein (Liquori et al., 2001). The intron contains a 
complex repeat motif, (TG)n(TCTG)n(CCTG)n. On normal alleles, the overall 
length of the CCTG portion ranges from 11 to 26 tetranucleotide repeats and 
on disease alleles from ~75 to more than 11 000. The presence of the repeat 
expansion results in nuclear and cytoplasmic aggregation of CNBP mRNA 
(Jones et al., 2011). 
 
2.3.2 TITINOPATHIES 
Titinopathies are muscle diseases caused by mutations in TTN. The disorders 
have huge phenotypic variability ranging from mild late onset distal 
muscular dystrophies to severe life-threatening early onset skeletal and/or 
cardiac muscle diseases. 
 
2.3.2.1 Hereditary myopathy with early respiratory failure 
Hereditary myopathy with early respiratory failure (HMERF, OMIM 
#603689) was first described in seven unrelated families with autosomal 
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dominant inheritance in 1990 (Edström et al., 1990). The disease causes 
slowly progressive proximal and distal lower limb weakness with respiratory 
muscle involvement and can affect also upper limbs and axial muscles. The 
symptoms typically begin in the third to fifth decades of life. The disease 
severity varies among patients and the respiratory defect and distal leg 
weakness are usually the first symptoms. Some patients may require walking 
aids within a few years of onset, while others remain ambulant until their late 
70’s. Wheelchair dependence and the need for nocturnal noninvasive 
ventilatory support are common and the life expectancy of the patients is 
decreased (Edström et al., 1990). Histopathology of HMERF muscles shows 
myopathic-dystrophic changes with protein aggregations and rimmed 
vacuoles. HMERF pathology can be classified as a myofibrillar myopathy 
with myofibrillar abnormalities and characteristic cytoplasmic bodies, which 
are abnormal protein aggregates, often localized in subsarcolemmal position 
(Edström et al., 1990; Tasca et al., 2010). HMERF has been identified in 
several families worldwide. Two Swedish families showed a linkage to TTN 
locus and a heterozygous missense mutation (c.102271C>T, p.R34091W) in 
TTN exon 358 encoding the titin M-band kinase domain region was 
identified in 2005 (Lange et al., 2005). The mutation was shown to affect the 
interaction between titin and nbr1 and was thought to lead to pathogenic 
effect through a disruption of a signaling pathway that involves 
p62/SQSTM1, MuRF2 and SRF (Lange et al., 2005). The genetic cause in 
other HMERF families remained unknown until WES studies revealed a 
novel missense mutation in TTN exon 343 (Ohlsson et al., 2012; Pfeffer et al., 
2012). After this finding a missense mutation in TTN exon 343 was also 
identified in the original Swedish family with the kinase mutation and the 
role of the first identified mutation became unclear. Later the kinase 
mutation has been seen in healthy individuals and it cannot cause the disease 
alone, but it may cause the disease together with the exon 343 mutation 
(Hedberg et al., 2014a; Lange et al., 2014). 
 
2.3.2.2 Tibial muscular dystrophy and limb-girdle muscular dystrophy 
type 2J 
TMD (also known as Udd myopathy, OMIM #600334) was the first muscle 
disorder reported to be caused by mutations in TTN. It is an autosomal 
dominant disorder causing weakness and atrophy especially in the tibialis 
anterior muscles of the lower leg and progressing to the other anterior 
compartment muscles, extensor digitorum longus and extensor halluces 
longus. Symptoms include decreased ankle dorsiflexion, foot drop and 
problems with walking. Also proximal lower limb muscles gluteus minimus 
and hamstring muscles may be involved after the age of 60. The disorder is 
very mild and slowly progressive. Onset of weakness is usually after the age 
of 35, but may be as late as in the 60’s and most patients remain ambulant 
with normal life span (Udd et al., 1991; Udd et al., 1993). TMD is the most 
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common distal myopathy in Finland with prevalence up to 1/5000 (Udd, 
2007). The disorder is caused by mutations in the last two exons, 362 (Mex5) 
and 363 (Mex6), of TTN and they encode the unique sequence is7 and the 
M10 domain. The first described TMD mutation, FINmaj, was found in 
Finnish patients (Hackman et al., 2002). It is an 11-bp insertion/deletion 
mutation located in the last exon of TTN. It exchanges four amino acids 
(EVTW → VKEK) in the M10 domain. Later several other TMD mutations, 
including missense, nonsense, frameshift and in-frame deletion, in the last 
two exons of TTN have been identified in European families (Van den Bergh 
et al., 2003; Hackman et al., 2008; Pollazzon et al., 2010; Suominen et al., 
2012). Reported TMD mutations are listed in Table 4. 
 
Table 4. Reported TMD mutations (NM_001267550.1 and NP_001254479.1). 
Mutation Exon DNA Protein Reference 
French C 362 (Mex5) c.107647delT p.S35883Qfs*10 (Hackman et 
al., 2008) 







Italian 363 (Mex6) c.107837A>C p.H35946P (Pollazzon et 
al., 2010) 
Belgian 363 (Mex6) c.107840T>A p.I35947N (Van den Bergh 
et al., 2003) 
French A 363 (Mex6) c.107867T>C p.L35956P (Hackman et 
al., 2002) 
Iberian 363 (Mex6) c.107889delA p.K35963Nfs*9 (Hackman et 
al., 2008) 
French B 363 (Mex6) c.107890C>T p.Q35964* (Hackman et 
al., 2008) 







The FINmaj mutation causes a completely different and much more severe 
early-onset limb-girdle muscular dystrophy type 2J (LGMD2J) when 
homozygous (Udd et al., 1991; Udd, 1992; Udd et al., 1992; Udd et al., 2005). 
Only a few patients with the disorder have been diagnosed. The disease onset 
in the patients was in the first or second decades of life and the first 
symptoms were weakness and atrophy of proximal muscles, which then 
eventually progressed to all limb and trunk muscles. Severe disability with 
loss of ambulation occurred within 20 years. One patient homozygous for the 
French TMD mutation (c.107890C>T, p.Q35964*) has also been reported, 
but he showed a slightly different phenotype. The disease onset was at age 25 
and the first symptoms occurred in the proximal upper limbs. A generalized 
weakness and wasting in all four limbs was observed at the age of 47. The 
anterior compartments of arms and forearms, the quadriceps and anterior 
leg muscles showed pronounced involvement. The patient lost ambulation at 
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the age of 56. The elbow, wrist and finger extensor muscles remained 
relatively preserved in the upper limbs. The phenotype was not completely 
identical to the FINmaj homozygous LGMD2J patients as the age of onset 
was later, the first symptoms were in the upper limbs, and the proximal and 
distal muscles were equally involved in the first examination (Penisson-
Besnier et al., 2010). Recently a novel mutation c.107788T>C (p.W35930R) 
in TTN Mex6 was identified in three homozygous patients of a Chinese 
family with proximal lower and upper limb weakness and elbow and ankle 
joint contractures. The age of onset was in the teens and the patients lost 
ambulation before they were 30 years old. The family members having 
heterozygous mutation were healthy (Zheng et al., 2015). Atypical 
phenotypes in heterozygous TMD patients have been observed in about 9% 
of the patients. Some patients have had earlier disease onset compared to 
typical TMD, and in some patients also posterior or proximal lower limb 
muscles have been affected (Udd et al., 2005). 
 
Histopathology of TMD muscle shows myopathic-dystrophic changes. 
Rimmed vacuoles are present in anterior compartment muscles, but may be 
absent in other muscles, while LGMD2J muscles do not show rimmed 
vacuolar pathology (Udd et al., 1993; Udd et al., 1992; Udd et al., 2005). 
 
Majority of the reported TMD mutations are located in TTN Mex6, which 
encodes the last M10 domain of titin. Known ligands for this domain are 
obscurin, obscurin-like 1 and myospryn (Fukuzawa et al., 2008; Sarparanta 
et al., 2010). The mutations have been reported to decrease binding ability of 
titin to obscurin and in LGMD2J muscles mislocalization of obscurin has 
been observed. Differences in severity between FINmaj, French A and 
Belgian TMD mutations have been studied using yeast two-hybrid and 
glutathione S-transferase (GST) pulldown assays and the results have shown 
that the clinically more severe mutations, FINmaj and French A, clearly 
reduce titin-obscurin/obscurin-like 1 binding, whereas binding by the 
Belgian TMD mutation was not detectably reduced. The FINmaj and French 
A mutations disrupt key structural features of the M10 Ig-fold, while the 
Belgian TMD mutation is a structurally less severe missense mutation 
(Fukuzawa et al., 2008). Obscurin is a sarcomeric giant protein participating 
in myofibril organization and interacts with titin also in the Z-disc (Young et 
al., 2001). Myospryn is a muscle-specific protein of the tripartite motif 
superfamily and reported to function in vesicular trafficking and protein 
kinase A signaling (Benson et al., 2004; Reynolds et al., 2007). Myospryn has 
been reported to associate with costameres and the interaction of titin with 
myospryn could provide a link between the peripheral myofibrils and the 
costamere-like structures present at the M-band level (Sarparanta et al., 




The FINmaj mutation leads to a pathological cleavage of a larger part of the 
titin C-terminus with loss of titin is5-M10 region, according to western blot 
and immunofluorescence studies of LGMD2J muscles (Hackman et al., 
2002; Charton et al., 2015). The unique is7 region, encoded by Mex5, is 
located next to the M10 domain of titin. Mex5 is an alternatively spliced exon 
and leads to a variable expression of is7+ and is7− titin isoforms in different 
muscles (Kolmerer et al., 1996). The is7 region contains the M-line binding 
site for the muscle-specific protease calpain 3 (Sorimachi et al., 1995). 
According to yeast two-hybrid assay results the FINmaj, French A and 
Belgian TMD mutations do not directly affect the ability of calpain 3 to bind 
C-terminal titin, but since the FINmaj mutation induces a pathological 
proteolytic cleavage of C-terminal titin the binding site is lost and leads to 
secondary calpain 3 deficiency in LGMD2J, although the cleavage is not 
caused by calpain 3 (Charton et al., 2015). Normal proteolytic processing of 
C-terminal titin by calpain 3 may have important role in the regulation of 
normal muscle sarcomeric functions, and these still unexplored functions of 
normally occurring C-terminal fragments are totally disrupted in LGMD2J. 
Immunofluorescence studies suggested that the pathological cleavage takes 
place in the titin is4-is5-region and may be caused by the ubiquitous calpains 
(Charton et al., 2015). 
 
2.3.2.3 Other titinopathies 
Centronuclear titin myopathy (CNTM) is a congenital myopathy present at 
birth or infancy with variable degrees of progressive wasting of muscles and 
weakness involving cranial, axial, proximal, and distal muscles. CNTM is 
characterized by the presence of muscle fibers with numerous centrally 
localized nuclei in the absence of other significant histopathological lesions. 
Reported TTN mutations causing CNTMs are recessive compound 
heterozygous mutations, including frameshift, nonsense, splice site or 
missense mutations mainly in the A-band and M-line regions of TTN 
(Ceyhan-Birsoy et al., 2013). 
 
Early-onset myopathy with fatal cardiomyopathy (EOMFC), also known as 
Salih myopathy, is a titinopathy affecting both cardiac and skeletal muscles. 
It is a form of congenital muscular dystrophy with childhood-onset dilated 
cardiomyopathy (Carmignac et al., 2007). Recessive TTN mutations in two 
consanguineous families have been reported. The affected patients had 
delayed motor development and joint deformities with contractures that 
restricted the movement of the neck and back. Later in childhood scoliosis 
developed as well as cardiac failure, which progressed rapidly and eventually 
led to death. The TTN mutations were homozygous deletions causing 
frameshift in Mex1 (c.105528_105535del AGTGACCA, p.Gln35176Hisfs?9) or 
in Mex3 (c.106571delA, p.Lys35524Argfs?22). The heterozygous carriers 
were healthy. Truncated proteins were experimentally confirmed in the 
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patients’ skeletal and heart muscles (Carmignac et al., 2007). Later 
additional families were characterized and a more inclusive term multi-
minicore disease with heart disease (MmD-HD) was proposed. The reported 
MmD-HD families had homozygous or compound heterozygous nonsense, 
frameshift and missense mutations mainly in the Mex1 and Mex2 exons of 
TTN (Chauveau et al., 2014a). 
 
Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardio-
myopathy has been reported in three families with recessive truncating 
mutations in TTN exons Mex1-Mex3. The patients have limb-girdle weakness 
and early-onset elbow joint contractures. The biopsies showed rimmed 
vacuoles, a dystrophic pattern, and a secondary reduction in calpain 3 (De 
Cid et al., 2015). 
 
2.3.2.4 Titin cardiomyopathies 
TTN mutations are known to cause several types of cardiomyopathies. 
Dilated cardiomyopathy (DCM) is a heart muscle disorder characterized by 
dilated and poorly functioning left ventricle with disease onset usually in the 
adulthood. TTN mutations causing DCM have been reported to be dominant 
frameshift or nonsense mutations in the I- and A-band regions, missense 
mutations in the Z-disc, I-band and M-line, and mutations that are predicted 
to affect splicing in different parts of TTN (Itoh-Satoh et al., 2002; Gerull et 
al., 2002; Herman et al., 2012; Roberts et al., 2015). 
 
Hypertrophic cardiomyopathy (HCM) is characterized by thickening of the 
heart muscle and can lead to a sudden death. HCM can affect individuals of 
different ages. Reported TTN mutations causing HCM are dominant 
missense mutations in Z-disc or I-band TTN (Itoh-Satoh et al., 2002; Satoh 
et al., 1999; Arimura et al., 2009). Also frameshift, nonsense and splice site 
variants of unknown significance in HCM patients have been reported in 
different parts of TTN (Herman et al., 2012; Lopes et al., 2013). 
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized 
by fibro-fatty replacement of the right ventricular myocardium, which leads 
to cardiac arrhythmias and can cause sudden death. The disease usually 
begins in the teens or in early adulthood. Reported TTN mutations causing 
ARVC are mainly dominant missense mutations in the I- and A-band 
regions, but some patients have compound heterozygous mutations (Taylor 
et al., 2011). 
 
Restrictive cardiomyopathy (RCM) is a rare disorder characterized by 
restrictive filling of the ventricles with disease onset at adulthood. Dominant 
missense mutation in TTN I-band has been reported to cause this disease. 
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Mutations in several other cardiac genes are also known to cause 
cardiomyopathies (Peled et al., 2014). 
 
2.3.3 DIAGNOSTICS OF MYOPATHIES 
Diagnostic efforts in myopathies often require combinations of different 
methods. The primary starting point is the clinical evaluation, which 
provides information about the disease onset, affected muscle groups and 
symptoms of the patient. After that specific tests can be performed to get 
more information. Serum creatine kinase (CK) levels can be measured since 
an elevated level is a sign of muscle damage. Electromyography (EMG) is a 
technique used for evaluating the electrical activity produced by skeletal 
muscles, which helps to distinguish myopathic-dystrophic and inflammatory 
disease from neurogenic muscle wasting and weakness. Magnetic resonance 
imaging (MRI) is performed to characterize and localize the severity and 
pattern of muscle involvement. The MRI patterns of variable muscle 
involvement can be characteristic or even pathognomonic for certain types of 
dystrophies and are essential in the diagnostic process. Studies on muscle 
biopsy including histopathology, histochemistry, immunohistochemistry and 
Western blotting as well as electron microscopy are performed to observe 
abnormal changes in the structure of muscle fibers, inflammation, 
necrotizing features and to detect defective proteins either as loss of protein 
or abnormal accumulations. All these examinations are important for 
phenotyping when evaluating possible candidate genes for genetic testing, 
which is required to obtain the exact genetic diagnosis. NGS methods have 
increased the utility of genetic testing dramatically and targeted gene panels 
containing myopathy genes are often used when no clear candidate gene can 
be suspected or if the candidate gene is too large for conventional Sanger 
sequencing. The family history, phenotype characteristics as well as other 
clinical data is nevertheless essential when interpreting the NGS results 
(Bushby, 2009; Fardeau and Desguerre, 2013; Bönnemann et al., 2014). 
 
2.3.3.1 Gene panels for myopathies 
The first reported targeted NGS assay in the field of myopathies included 
only one large gene, DMD, and it was developed to detect mutations in DMD 
and BMD patients (Bonnal et al., 2010). In the assay long PCR combined 
with massive pyrosequencing was used and 3X coverage was sufficient for 
99.99% accuracy. Later Lim et al. described a custom solution-based target 
enrichment using the Agilent SureSelect kit with barcode multiplexing and 
massively parallel sequencing by Illumina Genome Analyser (2 × 69 cycles) 
to detect both small mutations and CNVs in DMD (Lim et al., 2011). Xie et al. 
described an assay capturing DMD by NimbleGen array-based hybridization 
chip and sequencing using Illumina HiSeq2000 (2 × 90 bp reads) (Xie et al., 
2012). NGS assay for TTN has also been developed as Herman et al. 
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described an assay to detect TTN mutations in cardiomyopathies. TTN was 
enriched by filter-based hybridization capture and sequenced with Illumina 
Genome Analyzer II or HiSeq (single-end or paired-end). CNVs were 
analyzed by comparing the distribution of sequence reads among subjects. 
One duplication was detected and its presence was confirmed (Herman et al., 
2012). 
 
Other reported targeted gene panels for myopathies contain more genes. 
Vasli et al. described NMD-seq, which can capture and sequence 256 
neuromuscular genes simultaneously. Targeted regions were captured using 
the Agilent SureSelect custom target enrichment kit and the enriched DNA 
fragments were barcoded, pooled by four, and sequenced on Illumina 
Genome Analyzer IIx to generate 72 bp paired-end reads. A coverage-based 
method was used to analyze CNVs and one large deletion was identified 
(Vasli et al., 2012). Valencia et al. described a gene panel containing 12 
congenital muscular dystrophies genes. They used two different methods to 
capture targets: RainDance microdroplet-based PCR and a custom Agilent 
SureSelect solution-based hybridization and for sequencing the SOLiD 
platform (Valencia et al., 2012). Savarese et al. described MotorPlex gene 
panel containing 93 genes causing nonsyndromic muscle disorders. Agilent 
HaloPlex target enrichment system was used and the libraries were 
sequenced using the HiSeq1000 (Savarese et al., 2014). Chae et al. described 
a gene panel containing 579 genes associated with myopathies including also 
potential candidate genes. They used Agilent Haloplex capturing system and 
sequenced using Illumina Genome Analyzer IIx instrument (2 × 100 bp) 
(Chae et al., 2015). Sevy et al. described a gene panel for 298 neuromuscular 
disease genes using Agilent HaloPlex enrichment system and for sequencing 
Ion PGM sequencer (Sevy et al., 2015). Dai et al. described a gene panel for 
44 genes associated with muscular dystrophies and congenital myopathies 
using NimbleGen custom capture array and paired-end sequencing with 
Illumina HiSeq2000 (Dai et al., 2015). The performances of the gene panels 
have been overall good and they have provided high sensitivity and 
specificity. 
 
2.3.4 TREATMENT OF MYOPATHIES 
Currently there is no cure for inherited myopathies, but certain therapies and 
medications aim to treat the problems resulting from the disorders and 
improve the quality of life for patients. Supportive care for muscular 
dystrophies include physical therapy, occupational therapy, orthopedic 
surgery, genetic counseling, invasive and noninvasive mechanical ventilation, 
and the use of implanted cardiac devices. Pharmacological, gene and cell 
therapies are under development. The main focus has been on DMD, which 




Pharmacological treatments for myopathies have been limited. Cortico-
steroids have been shown to improve skeletal muscle strength and function 
in DMD patients. For myotonic dystrophy patients mexiletine, a sodium-
channel blocker, have been used to reduce myotonia. Pharmacological 
therapies under development include myostatin inhibitors and insulin-like 
growth factor 1, which induce muscle regeneration. One promising 
pharmacological treatment for DMD aims to increase levels of utrophin, a 
homolog of dystrophin, to compensate for the absence of dystrophin. 
Compounds that can induce ribosomal read-through of nonsense mutations 
have also been identified and they could help DMD patients with premature 
termination codons (Leung and Wagner, 2013; Abdel-Hamid and Clemens, 
2012). 
 
Gene and cell therapies for different myopathies are under development. 
Many of the gene-based approaches utilize antisense oligonucleotides, which 
are small 20–30 nucleotides long single-stranded DNA or RNA sequences 
that can target gene transcripts and modulate splicing patterns or inhibit 
protein translation. Antisense-mediated transcript targeting approaches have 
been developed for DMD, which is caused by mutations that disrupt the open 
reading frame of DMD. To restore the open reading frame an exon-skipping 
treatment has been developed, which results in the milder BMD disease. 
Antisense oligonucleotide-based approaches have also been developed to 
treat other myopathies including dysferlinopathies and laminopathies by 
bypassing mutation in in-frame exon, Fukuyama muscular dystrophy by 
skipping of cryptic retrotransposon exon, OPMD by polyadenylation site 
usage, DM1 by reduced levels of mutated transcript and Pompe disease by 
reduced levels of glycogen synthase. The DMD and DM1 therapies have 
advanced to the clinical trial phase (Jirka and Aartsma-Rus, 2015). Also 
other gene therapy approaches have been developed for DMD, because all 
DMD mutations cannot be treated with antisense oligonucleotides. In one of 
the approaches, an alternate copy of dystrophin is delivered using 
recombinant adeno-associated virus, which has shown the most potential. 
Shortened but functional forms of dystrophin, small enough to be packaged 
within the virus capsid, have been designed for the treatment (Ramos and 
Chamberlain, 2015). Adeno-associated virus-based vectors are also under 
development to treat myotubular myopathy and metabolic myopathies 
(Childers et al., 2014; Mah et al., 2013). 
 
Cell therapy is another potential treatment for myopathies. It can be seen as 
a form of gene therapy if the functional gene or protein is directly delivered 
using cells as vectors. Cell therapy involves the purification of adult stem 
cells from the patient, correction of the genetic defect, expansion of the 
corrected cells and reinjection of the cells into the patient. Alternatively cells 
from healthy donors can be used, but they can lead to rejection. A fusion of 
the stem cells into myofibers allows delivery of the corrected gene. Different 
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cell types have been considered as candidates for cell therapy in 
neuromuscular diseases. One of them are myoblasts, which are able to fuse 
with host myofibers and deliver normal proteins, but long-term engraftment 
is limited because of low cell survival, since the myoblasts are unable to 
migrate throughout the damaged tissue. Since the intramuscular injection of 
myoblasts leads to localized tissue repair at the site of injection, for 
conditions like OPMD or FSHD, which have a limited number of muscles 
affected, the myoblast transplantation is applicable. In order to treat every 
muscle, the cells would need to be injected into the bloodstream. 
Mesoangioblasts are vessel-associated stem cells able to differentiate into 
several mesodermal cell types including myotubes. Injected mesoangioblasts 
cross the vessel barrier and migrate into the dystrophic muscle where they 
participate in muscle regeneration. Pluripotent stem cells, such as embryonic 
stem cells and induced pluripotent stem cells, provide an alternative 
therapeutic agent to treat muscular dystrophies that affect large muscle 
groups because of their capacity for migration and self-renewal (Negroni et 
al., 2015; Wilschut et al., 2012).  
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3 AIMS OF THE STUDY 
The aims of the study were: 
 
1. To identify causative mutations in unclarified muscular dystrophy 
patients and families using NGS methods. 
 
2. To identify additional mutations in patients having heterozygous TMD 
mutations, but more severe or complex phenotypes. 
 
3. To develop a targeted NGS gene panel, MyoCap, for detection of 




4 MATERIALS AND METHODS 
4.1 PATIENTS AND SAMPLES 
A total of 107 muscular dystrophy patients from various countries and ethnic 
origins were included in this doctoral study. The study was approved by the 
local ethics committees and samples were obtained according to the Helsinki 
declaration. 
 
4.1.1 PATIENTS IN THE HMERF STUDY (I) 
31 affected patients, 16 males and 15 females, and their 26 healthy family 
members were included in the HMERF study. The patients were from 12 
unrelated HMERF families from Finland, Sweden, France, Germany, Italy, 
United Kingdom and Argentina. The DNA samples were provided by the 
clinicians in different countries. The diagnosis of HMERF was based on 
clinical symptoms of respiratory insufficiency together with muscle weakness 
and/or presence of cytoplasmic bodies in muscle biopsy and a typical pattern 
of muscle involvement on MRI. 
 
4.1.2 PATIENTS IN THE TMD COMPLEX STUDY (II) 
Eight patients from seven families were included in the TMD complex study. 
The families were from Finland, France, Spain and Portugal. The patients 
had a previously reported TMD mutation, but a more severe or complex 
phenotype. DNA samples of the patients and healthy family members were 
obtained from clinicians in the corresponding countries. Muscle biopsy 
tissues were available from all the patients. 
 
4.1.3 PATIENTS IN THE MYOCAP STUDY (III) 
Altogether 65 patients were included in the MyoCap study. Four of the 
patients served as mutation controls with previously reported mutations, and 
61 were unsolved myopathy patients despite of extensive diagnostic 
approaches. The patients were from 15 different countries and the DNA 
samples were from their corresponding clinicians. 14 of the patients had 
dominant disease, 11 recessive and 36 were sporadic. 
 
4.1.4 PATIENTS IN THE RECESSIVE DISTAL TITINOPATHY STUDY (IV) 
Ten patients and 16 healthy family members from six unrelated families were 
included in the recessive distal titinopathy study. The families were from 
Albania, Bosnia, Iran, Tunisia and Spain. The DNA samples were sent by the 
54 
 
corresponding clinicians in different countries and muscle biopsy tissues 
were available from three patients. All the patients had a recessive distal 
myopathy phenotype with childhood or early adult onset and healthy 
parents. 
4.2 METHODS 
4.2.1 SANGER SEQUENCING (I-IV) 
Sanger sequencing was performed to identify mutations, confirm NGS 
findings and also to assess the segregation of the mutation with the disease in 
the families. Primers were designed using Primer3 software 
(http://bioinfo.ut.ee/primer3-0.4.0/) and PCR was performed using 
DreamTaq™ DNA Polymerase (Thermo Scientific) according to standard 
protocol. The PCR products were purified with Exonuclease I (Thermo 
Scientific) and FastAP Thermosensitive Alkaline Phosphatase (Thermo 
Scientific), and sequenced on ABI3730xl DNA Analyzer (Applied Biosystems) 
at the Institute for Molecular Medicine Finland (FIMM), using the Big-Dye 
Terminator v3.1 kit. The sequences were analyzed using Sequencher 5.0 
software (Gene Codes Corporation). 
 
4.2.2 EXTRACTION OF RNA FROM MUSCLE TISSUE AND RT-PCR (II-
IV) 
The consequences of frameshift, nonsense and splice site mutations were 
studied by sequencing cDNA. Total RNA was extracted from frozen muscle 
biopsies with RNeasy Fibrous Tissue Mini kit (Qiagen) or Direct-zol™ RNA 
MiniPrep Kit (Zymo Research) according to manufacturer’s instructions. 
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) or RevertAid H Minus Reverse Transcriptase (Thermo 
Scientific) following the instructions. PCR was performed using DreamTaq™ 
DNA Polymerase (Thermo Scientific). When required the amplified products 
were size separated by agarose gel electrophoresis and the fragments were 
extracted using QIAquick Gel Extraction Kit (Qiagen). 
 
4.2.3 GENOTYPING (I, IV) 
Families were genotyped using up to 13 microsatellite markers around the 
TTN locus: D2S2314, D2S1244, D2S138, D2S148, D2S2173, D2S300, 
D2S385, D2S324, D2S2978, D2S2261, D2S384, D2S364, and D2S350. The 
fluorescently-labeled PCR products were analyzed using ABI3730xl DNA 
Analyzer and GeneMapper v4.0 software (Applied Biosystems). The 





4.2.4 WHOLE EXOME SEQUENCING (I) 
Whole exome sequencing was performed at the Axeq/Macrogen laboratory in 
South Korea. The DNA enrichment was performed using Illumina TruSeq™ 
Exome Enrichment Kit and the DNA fragments were sequenced on Illumina 
HiSeq 2000 platform with 100 bp paired-end reads. 
 
4.2.5 TARGETED NEXT-GENERATION SEQUENCING (III, IV) 
The MyoCap gene panel was developed for detection of mutations in patients 
with primary myopathies. Altogether 180 myopathy related genes were 
included in the first version of the panel. The target region contained coding 
exons and 3' and 5' UTRs of transcripts present in databases RefSeq, 
Ensembl, CCDS, Gencode and VEGA. The total size of the target region was 
1.3 Mb containing 3999 exons. 
 
Capture probes (custom SeqCap EZ Choice Library, Roche NimbleGen) were 
designed using NimbleDesign (Roche NimebleGen) and 50-105-mer probes 
were allowed to have up to five close matches in the genome. DNA 
enrichment and next-generation sequencing were performed at FIMM. 
Sample libraries were processed according to NEBNext DNA Sample Prep 
Master Mix Set 1 (New England BioLabs) and four barcoded libraries were 
pooled to each capture reaction using the designed custom SeqCap EZ Choice 
Library and following the SeqCap EZ instructions (Roche NimbleGen). 100 
bp paired-end sequencing was performed using Illumina HiSeq 1500 with 
sequencing depth of 100X. 
 
4.2.6 BIOINFORMATICS METHODS (I, III, IV) 
Sequencing reads from WES were aligned to the human reference genome 
(UCSC hg19) using BWA and the variant calling was performed following 
GATK’s best practices. Variant filtering was performed using the analysis and 
visualization program RikuRator (unpublished, created by Riku Katainen 
from Lauri Aaltonen lab, the University of Helsinki). 
 
Sequencing reads from MyoCap were aligned to the human reference 
genome (UCSC hg19) using BWA. SAMtools was used to remove duplicates. 
Realignment around indels and base quality score recalibration were 
performed using GATK and variant calling was performed using both GATK 
and SAMtools. Annovar was used to annotate the variants. Exonic and splice 
site variants, within 15-bp of splice junctions, were analyzed. Variants with 
allele frequency higher than 1% in 1000 Genomes or ESP6500 databases 
were filtered out. The Human Gene Mutation Database (HGMD Professional 
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2014.3) was used to detect previously reported pathogenic mutations and 




5 RESULTS AND DISCUSSION 
5.1 NOVEL MUTATIONS IN TTN 
5.1.1 MUTATIONS IDENTIFIED IN THE HMERF PATIENTS (I) 
Study I included 12 unrelated HMERF families from seven different 
countries. Two of the families were from the original report and two were 
other previously reported families with HMERF phenotype, but with 
unsolved genetic cause (Edström et al., 1990; Tasca et al., 2010; Chapon et 
al., 1989). Altogether 31 patients, 16 males and 15 females, and 26 healthy 
family members were studied. The mean age of disease onset was 36.6 years 
ranging from 16 to 53. The patients had distal and proximal lower limb 
weakness and respiratory insufficiency. Neck flexor, abdominal and ankle 
dorsiflexion weakness was marked. Muscle weakness was progressive and 
usually symmetrical. At onset upper limbs were not affected, but in the later 
course proximal and distal weakness in the upper extremities was observed. 
The severity of muscle weakness and the rate of progression varied from mild 
to loss of ambulation at age 36 years. Typical pathological findings included 
fiber-size variation, increase of internal nuclei, cytoplasmic bodies and 
rimmed vacuoles. 
 
In 2012, studies using WES identified a novel dominant missense mutation 
(p.C31712R) in TTN A-band exon 343 in three Swedish and three British 
families (Ohlsson et al., 2012; Pfeffer et al., 2012). During the same time our 
study using WES revealed a novel missense mutation (p.P31709R) in TTN 
exon 343 in a French HMERF family. TTN exon 343 was then Sanger 
sequenced from the rest of the studied HMERF families and altogether five 
different TTN missense mutations in the 12 unrelated HMERF families were 
identified (Table 5). One of the mutations (p.C31712R) was the recently 
reported, but the four others were novel. All the mutations were located in 
the same TTN exon 343, encoding FN3 domain in the titin A-band region, 
and they all changed a conserved amino acid. Family members were also 
Sanger sequenced and the mutations segregated with the disease in the 
families. All the mutations were dominant except one (p.P31732L), which 





Table 5. Identified TTN mutations in the HMERF families (NM_001267550.1 and 
NP_001254479.1). 
Family Ethnicity Exon DNA Protein 
A French 343 c.95126C>G p.P31709R 




343 c.95134T>C p.C31712R 
I British 343 c.95185T>C p.W31729R 
H German 343 c.95187G>C p.W31729C 
J, K, L Italian, two 
French 
343 c.95195C>T p.P31732L 
 
Previous linkage studies in the French family A had excluded the TTN locus 
(Xiang et al., 1999), but re-classification of some of the individuals showed 
that the disease was indeed linked to the TTN locus. Families B, C, D, E, F 
and G sharing the mutation p.C31712R and families J, K and L sharing the 
mutation p.P31732L were genotyped using eight microsatellite markers 
flanking the TTN locus. Families B, C, D, E, F and G shared also the same, 
although short (<1.3 Mb), haplotype including two markers, D2S300 and 
D2S385, suggesting a common origin of the mutation. Families J, K and L 
shared another haplotype including the same two markers, also suggesting a 
common origin. 
 
The p.C31712R mutation is the most common of the HMERF mutations 
identified so far. It was first identified in three Swedish and British families 
(Ohlsson et al., 2012; Pfeffer et al., 2012). Our study added six more families, 
two from Sweden and one from Finland, Britain, Italy and Argentina with 
Caucasian, probably Italian, ancestry. Later the same mutation has been 
identified in five new British and one Canadian (with British ancestry) and 
Spanish families (Pfeffer et al., 2014; Pfeffer et al., 2014a; Toro et al., 2013). 
In addition, the same mutation has also been found in one Canadian family 
with Indian ancestry, but with a different haplotype than in the original 
British families, indicating a de novo mutation (Toro et al., 2013; Pfeffer et 
al., 2014b) and from one Chinese family with a new haplotype, which shared 
the core haplotype with the Canadian family with Indian ancestry (Yue et al., 
2015). The mutation is dominant with full penetrance, but its prevalence is 
unknown as HMERF is considered to be an under-diagnosed disease and 
probably a lot more common than expected (Pfeffer et al., 2014). 
Identification of different disease alleles with the same mutation suggest that 
this position in TTN may be a mutational hotspot and de novo mutations in it 
may arise in different ethnic groups. 
 
Families A, I and H from France, Britain and Germany had all different 
missense mutations, p.P31709R, p.W31729R or p.W31729C, which 
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segregated with the disease in the families. The mutations were dominant 
with full penetrance. They were located in the same region as the p.C31712R 
mutation and the patients had identical phenotypes, age of onset and disease 
severity as the patients with the p.C31712R mutation. Later other single 
families with novel dominant missense mutations in the same TTN exon 343 
have been reported. A novel c.95358C>G (p.N31786K) mutation was 
identified in a Brazilian family, a novel c.95372G>A (p.G31791D) mutation in 
an American family and a novel c.95186G>T (p.W31729L) mutation in a 
Japanese family (Pfeffer et al., 2014; Toro et al., 2013; Izumi et al., 2013). 
 
The p.P31732L mutation identified in families J, K and L is clearly more 
complicated, since the penetrance is not fully dominant. In families J and K it 
shows recessive and in family L dominant inheritance. However, the 
homozygous patients in families J and K have a more severe disease with 
earlier onset and more rapid progression than the heterozygous patients in 
family L, whose respiratory insufficiency occurred at a much later age and 
without clear limb muscle weakness. The heterozygous parents in family J 
showed subclinical myopathy in MRI with some fatty degenerative change in 
HMERF typical muscles. Since this mutation may or may not cause clinically 
manifested disease in heterozygous state, and it causes a clearly more severe 
phenotype in homozygosity, we called this mutation semirecessive in the 
corresponding publication. Another alternative could be that the 
manifestation of a milder HMERF in the family L could be the result of a 
second gene defect segregating with the disease and interfering with the 
molecular pathways affected by the TTN exon 343 mutation. During the 
same time the p.P31732L mutation was also reported in one heterozygous 
patient of a British family who also had a 61-year-old brother as a healthy 
carrier of the mutation (Pfeffer et al., 2014). Later it has been reported in a 
Chinese patient as a de novo mutation (Yue et al., 2015). The mutation has 
also been observed in WES project in heterozygous state in a single patient, 
but without further confirmation of its possible pathogenicity (Vasli et al., 
2012). The original Swedish HMERF families having the titin kinase 
mutation c.102271C>T (p.R34091W) in exon 358 (Mex1) (Lange et al., 2005) 
also had the p.P31732L mutation in cis and the HMERF disease in them is 
likely caused by the combination of these mutations (Hedberg et al., 2014a; 
Lange et al., 2014). The titin kinase mutation has later been seen in general 
population and has an allele frequency of 0.1% (rs140319117) in ExAC. Also 
the c.95195C>T (p.P31732L) mutation has been observed in general 
population with allele frequency of 0.0017%. The heterozygous patients in 
family L did not have the titin kinase mutation in addition to the p.P31732L 
mutation, but they may have some other additional pathogenic variant, 
which remains to be clarified. 
 
Hedberg et al. have studied how the HMERF mutations, p.P31709R, 
p.C31712R, p.W31729R, p.W31729C and p.P31732L, affect the biochemical 
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behavior of this titin FN3 A-band domain and all the mutations resulted in 
impaired FN3 domain solubility, which was not seen in amino acid changes 
associated with common SNPs of the same region. In silico analyses further 
supported the notion that the reported mutations impair proper folding of 
the FN3 domain (Hedberg et al., 2014b). 
 
5.1.2 ADDITIONAL TTN MUTATIONS IDENTIFIED IN THE COMPLEX 
TMD PATIENTS (II) 
Eighteen patients with heterozygous FINmaj TMD mutation, but more severe 
or complex phenotypes were described in 2005 (Udd et al., 2005). The 
patients had unusual TMD phenotypes including proximal leg or posterior 
lower leg muscle weakness and atrophy. Two of the patients had disease 
onset in childhood and a phenotype that resembled more of LGMD2J, caused 
by homozygous FINmaj mutation. One of the patients presented with 
generalized weakness from early infancy without further progression until 
adolescence with some increasing weakness. The other patient had proximal 
lower limb muscle weakness with onset at age 7 and a slowly progressive 
LGMD phenotype with moderate walking difficulties at age 17 (Udd et al., 
2005). These two patients were included in Study II and they represent 
patients 2 and 3. In 2008, a novel TMD mutation c.107647delT 
(p.S35883Qfs*10) in TTN Mex5 was identified in a French family with two 
affected members, a mother and a son (Hackman et al., 2008). They had a 
more severe distal phenotype when compared to the TMD and a disease 
onset at 20-30 years. The muscle weakness progressed to proximal muscles 
and also to arm muscles in the son. Later the patients also had dysphagia. 
Unequal expression of the TTN alleles was observed in RT-PCR and Western 
blot studies (Hackman et al., 2008). These two patients were also included in 
the Study II and they represent patients 5A and 5B. In addition, four other 
patients, 1, 4, 6 and 7, were included. Patient 1 had proximal muscle 
weakness starting from infancy. Patient 4 had a novel titinopathy phenotype 
starting at age 30 with muscle atrophy in the right calf, which progressed to 
the right thigh and then to the left thigh. Muscle biopsy showed dystrophic 
changes and rimmed vacuoles. Patient 6 had a disease onset in childhood 
with progressing distal muscle weakness in the lower limbs and mild 
weakness in the proximal lower limb muscles. Patient 7 had an early adult 
onset disease with slowly progressive distal and proximal muscle weakness in 
the lower limbs. 
 
Muscle biopsies were available from the patients and RT-PCR and Western 
blotting studies were performed. RT-PCR spanning TTN exons Mex4-Mex6 
or Mex5-Mex6 showed higher signal from the TMD mutated allele in the 
sequenced patients 1, 3, 5A and 5B suggesting unequal expression of the TTN 
alleles (Figure 7). Western blot using antibodies for M10 domain of titin 
showed loss of epitope recognition in patients 1, 3, 5A, 6 and 7 (patient 2 and 
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5B were not tested). The Western blot results looked similar to the blots of 
FINmaj homozygous LGMD2J muscle. The RT-PCR and Western blot results 
suggested a presence of second probably truncating and NMD-causing 
mutation on the other TTN allele. 
 
 
Figure 7. The cDNA sequencing chromatograms showed higher signal from the FINmaj 
mutated allele (patient 3) and French Mex5 mutated allele (patient 5A) compared to the 
other TTN allele. 
Sanger sequencing of TTN from patients’ genomic DNA was performed in 
order to identify the additional mutations. Sequencing was performed 
starting from the last exon of TTN and continuing upstream as majority of 
TTN mutations had previously been found in the end of the gene. Sequencing 
revealed six novel TTN mutations (Table 6). Patients 1, 2, 5A, 5B and 6 were 
compound heterozygotes having the previously reported TMD mutation in 
combination with a novel TTN frameshift mutation, patient 7 was 
homozygous for the previously reported Iberian TMD mutation and patient 4 
with the new titinopathy phenotype had a novel missense mutation in TTN 
A-band exon 339 in combination with the FINmaj TMD mutation. Patient 3 
with the heterozygous FINmaj TMD mutation and LGMD phenotype was not 
clarified, although every exon of TTN was sequenced and the RT-PCR and 
Western blot results had suggested an additional mutation on the other TTN 
allele. It is possible that the mutation may have gone undetected because of 
faulty primers or if the mutation is located in a deep intronic region or if it is 




Table 6. Identified TTN mutations in the complex TMD patients (NM_001267550.1 and 
NP_001254479.1). 
Patient Reported TMD mutation Novel TTN mutation Phenotype 











2 Exon 363, FINmaj 
(paternal) 





3 Exon 363, FINmaj 
(maternal) 
not found LGMD 
4 Exon 363, FINmaj 
(maternal) 
Exon 339 (A-band) 
c.92167C>T 
p.P30723S     
(paternal) 
novel titinopathy 
5A Exon 362, French 
c.107647delT 
p.S35883Qfs*10 




5B Exon 362, French 
(maternal) 














7 Exon 363, Iberian 
(homozygote,        
maternal and paternal) 
- severe TMD 
 
The frameshift mutation regions were sequenced from cDNA of patients 1, 2, 
5A, 5B and 6. The sequencing chromatograms showed a lower signal from 
the frameshift alleles compared to the TMD alleles and were in concordance 





Figure 8. The cDNA sequencing chromatograms showed a lower signal from the frameshift 
alleles compared to the TMD alleles. 
All the novel frameshift mutations identified in this study cause a premature 
stop codon in the sequence and are located >50-55 nucleotides upstream of 
the last exon-exon junction making them likely to trigger NMD (Nagy and 
Maquat, 1998). NMD is a surveillance pathway that functions to reduce 
errors in gene expression by degrading mRNAs that contain premature stop 
codons, which would otherwise lead to translation of erroneous proteins. 
NMD is often incomplete, but the amount of translated truncated titin 
protein from the frameshift alleles was not studied. If the truncated protein is 
translated it does not seem to have any dominant effect as individuals 
carrying the novel frameshift mutation, the fathers of patients 1 and 6 and 
the mother of patient 2, were healthy at age 53-64. This indicates that the 
frameshift alleles are recessive and not able to cause disease alone. The 
compound heterozygous patients with TMD and frameshift mutations had 
similar phenotypes as the homozygous patients with the corresponding TMD 
mutation. Frameshift and nonsense mutations in different parts of TTN A-
band region have previously been reported to cause dominant cardiomypathy 
(Herman et al., 2012). The cardiomypathy mutations were first thought to 
cause the disease by means of dominant negative mechanism, but according 
to new studies haploinsufficiency is more likely (Roberts et al., 2015; Hinson 
et al., 2015). The penetrance of TTN truncating mutations in DCM was more 
than 95% for the subjects who were more than 40 years of age (Herman et 
al., 2012). This was not the case in the patients of our study and it remains to 
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be clarified why some TTN frameshift mutations cause cardiomyopathy, 
while some do not. 
 
Phenotypic variability between different TMD mutations has been observed. 
In heterozygous state the reported Mex6 TMD mutations cause a somewhat 
similar distal myopathy with weakness in the lower limbs. An exception is the 
Belgian TMD mutation, which causes a milder phenotype (Van den Bergh et 
al., 2003). It has been explained that the FINmaj and French A mutations 
disrupt key structural features of the M10 Ig-fold, while the Belgian TMD 
mutation is a structurally less severe missense mutation. FINmaj and French 
A mutations have been shown to reduce the binding of obscurin/obscurin-
like 1 to titin, while the Belgian TMD mutation did not have this effect 
(Fukuzawa et al., 2008). Our study shows that the previously reported 
Iberian TMD mutation can have reduced penetrance and the mutation 
carriers can be asymptomatic. This was observed in the parents of patient 7 
and the mother of patient 6, who were heterozygous for the Iberian TMD 
mutation, but healthy at age of 55-60 years. It is possible that the parents 
may have a very late disease onset. The Iberian TMD mutation is a single 
nucleotide deletion leading to a frameshift in the end of the gene. Likely this 
region is not as important as the FINmaj mutation region of the domain. 
 
Phenotypic variability has also been observed in the homozygous or 
compound heterozygous patients with TMD mutations. The FINmaj 
mutation has been shown to cause a severe childhood onset LGMD 
phenotype in homozygous patients (Udd et al., 1991; Udd, 1992; Udd et al., 
1992). Quite similar early onset LGMD phenotype was also observed in 
patients 1 and 2 who had the heterozygous FINmaj mutation in compound 
heterozygosity with a frameshift mutation. Also patients homozygous for the 
French c.107890C>T (p.Q35964*) and Chinese c.107788T>C (p.W35930R) 
Mex6 mutations have been reported to have an LGMD phenotype (Penisson-
Besnier et al., 2010; Zheng et al., 2015). The Chinese mutation is located in 
the same region as the FINmaj mutation, which may explain the similar 
phenotypes caused by the mutations. The French patient had a milder 
phenotype than LGMD2J with a later disease onset at 25 years. The first 
symptoms were in the upper limbs and the proximal and distal muscles were 
equally involved in the first examination (Penisson-Besnier et al., 2010). The 
French mutation is located close to the Iberian TMD c.107889delA 
(p.K35963Nfs*9) mutation, which does not cause an LGMD phenotype in 
homozygosity or compound heterozygosity with a frameshift mutation, but 
rather a more severe distal phenotype as seen in patients 6 and 7. Both of 
these mutations cause frameshift and loss of about the last third of the Mex6 
exon. Patients 5A and 5B had the previously reported French Mex5 mutation 
c.107647delT (p.S35883Qfs*10) (Hackman et al., 2008) in compound 
heterozygosity with a frameshift mutation. The Mex5 mutation causes a 
frameshift in the end of Mex5 and a total loss of Mex6 resulting in the loss of 
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M10 domain. Heterozygotes with this mutation are not known, but the 
compound heterozygous patients, 5A and 5B, have similar more severe distal 
phenotype as the compound heterozygous or homozygous patients 6 and 7 
with the Iberian TMD mutation. Mex5 is an alternatively spliced exon and 
not present in all skeletal muscle isoforms. This means that some of the 
isoforms skip the mutation and are normal. This could explain why the 
mutation does not lead to the more severe LGMD phenotype. Mex5 encodes 
is7, which contains the M-line calpain 3 binding site (Sorimachi et al., 1995). 
When studying calpain 3 levels by Western blotting patient 5A showed 
normal levels whereas patients 1, 3, 6 and 7 showed clear reduction, similar 
as seen in the LGMD2J muscle, which is in line with the Mex5 mutation 
having no effect in is7- isoforms of titin. 
 
Patient 4 with a new titinopathy phenotype had a novel missense mutation 
c.92167C>T (p.P30723S) in TTN exon 339, encoding for FN3 domain in the 
A-band region, in compound heterozygosity with the FINmaj TMD mutation. 
The patient had inherited the missense mutation from his healthy father and 
the FINmaj mutation from his TMD mother. The patient, however, had a 
disease that was completely different from both TMD and LGMD2J. The 
onset was at the age of 30 years and started with muscle atrophy of the right 
calf, progressing to the right thigh and then to the left thigh requiring a stick 
for walking at the age of 45 years. The tibialis anterior muscles were 
relatively spared. How the combination of these two mutations cause the 
phenotype remains to be clarified. 
 
5.1.3 TTN MUTATIONS IDENTIFIED IN THE MYOCAP GENE PANEL 
SCREEN (III) 
The MyoCap targeted gene panel was developed to enhance the genetic 
testing of unsolved myopathy patients. TTN mutations identified in the first 
screen are discussed in this chapter and the panel itself in the later chapters. 
Altogether 61 research patients negative for previous candidate gene 
approaches were included in the first screen and nine of them had 
pathogenic TTN mutations (Table 7). Two of the patients (P8 and P9) 
received definite diagnosis, four patients (P13-P16) probable diagnosis and 
three patients (P19-P21) with recessive disorders, were identified with one 




Table 7. TTN mutations identified in the first MyoCap screen (NM_001267550.1 and 
NP_001254479.1). AR = autosomal recessive, S = sporadic. 
Patient 























































TTN:exon363:c.107889delA:p.K35963fs reported AR Distal myopathy 
P20 
Italy 









Patient P8 had the previously reported Iberian TMD mutation in compound 
heterozygosity with a novel frameshift mutation in A-band exon 326. The 
patient had muscle weakness in the lower limb muscles starting at age four. 
The phenotype was compatible with the previously reported patient (Study 
II) with the Iberian TMD mutation and a compound heterozygous A-band 
frameshift mutation. 
 
Patient P9 had a novel missense mutation in exon 363 (Mex6) in compound 
heterozygosity with a novel frameshift mutation in A-band exon 326. The 
patient had muscle weakness in lower limb muscles starting at age 24. The 
Mex6 mutation was located in the same region as the previously reported 
TMD mutations and the patient also had similar phenotype as the compound 
heterozygous patients having TMD and A-band frameshift mutations. 
 
Patient P13 had the previously reported Italian TMD mutation in compound 
heterozygosity with a novel missense mutation in A-band exon 304. The 
patient belonged to the previously reported Italian TMD family (Pollazzon et 
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al., 2010), but he had a different phenotype with a proximal thigh muscle 
weakness starting before the lower leg weakness. The patient had inherited 
the TMD mutation from his TMD father and the novel missense mutation 
from his healthy mother. The phenotype in this patient was almost identical 
to the phenotype that was reported in Study II in patient 4 having the 
FINmaj TMD mutation in compound heterozygosity with a novel missense 
mutation in A-band exon 339. These novel missense mutations are clearly 
recessive, but the mechanism of their pathogenicity requires clarification. 
 
Patient P14 was the only affected member in her family. She had a novel 
distal myopathy phenotype starting in the late childhood with mild distal 
weakness. At age 29 she had severe weakness of the anterior compartment 
muscles of legs and mild weakness in wrists, fingers, shoulders and hips. 
MyoCap revealed two novel TTN mutations. A novel missense mutation in A-
band exon 340 inherited from her healthy mother and a novel nonsense 
mutation in A-band exon 306 inherited from her healthy father. In addition, 
her brother with the missense mutation and her sister with the nonsense 
mutation were healthy. The pathogenicity of TTN missense mutations can be 
difficult to determine, but as the mutation c.94285T>A (p.W31429R) 
exchanges a conserved hydrophobic tryptophan, buried in the FN3 domain, 
to a positively charged arginine it most probably breaks the hydrophobic core 
of the domain and leads to an unfolded FN3. 
 
Patient P15 had two novel missense mutations in TTN, one in I-band exon 
107 (c.30326C>G, p.T10109R) and the other in M-line exon 358 
(c.105037C>T, p.R35013C). The exon 107 encodes an Ig-like domain in the 
N2A region, which contains the I-band binding site for calpain-3 (Sorimachi 
et al., 1995) making it an interesting candidate. The mutated region in the 
exon 358 (Mex1) encodes an Ig-like M4 domain in the titin M-line with 
unknown ligands. M4 was first reported to interact with myomesin 
(Obermann et al., 1997), but the interaction could not be repeated in 
additional experiments (Fukuzawa et al., 2008). The patient had a more 
severe weakness in the proximal and distal upper limbs and milder weakness 
in the lower limbs. The first diagnostic examination was at age 47 and he 
started to use the wheelchair at age 49. The patient had inherited the exon 
358 mutation from his father who had a milder phenotype with limb 
weakness after age 70. Also the patient’s son had the mutation and he was 
healthy at age 35. The findings are interesting, but more evidence is needed 
to confirm the pathogenicity of the mutations. 
 
Patient P16 had an HMERF phenotype and no family history with the 
disease. Two rare TTN variants were identified. One of them (c.95297C>T, 
p.S31766F) was located in the same exon 343 as the reported HMERF 
mutations, with an allele frequency of 0.4 % in ExAC (rs191484894). The 
other variant (c.100400T>G, p.V33467G) was in exon 357, encoding a 
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domain in the end part of A-band, with an allele frequency of 0.03 % in ExAC 
(rs200166942). The findings were considered highly interesting, since one of 
the reported HMERF mutations (p.P31732L) is more or less recessive and 
causes the disease in homozygosity or in combination with another mutation 
(p.R34091W) (Hedberg et al., 2014a; Lange et al., 2014). The findings of the 
patient P16 need more studies. 
 
Patients P19, P20 and P21 were identified having only one TTN mutation 
each, not sufficient to cause their diseases alone. Patient P19 had the 
previously reported Iberian TMD mutation, but more severe early onset 
phenotype with muscle weakness in the lower limbs. His brother with similar 
phenotype had the mutation too, but it was also present in their healthy 
father and sister. Iberian TMD causes a mild late onset dominant distal 
myopathy (Hackman et al., 2008), and additional mutation in the affected 
members would have been expected. Healthy carriers of the mutation have 
previously been found and in compound heterozygosity with a frameshift 
mutation the mutation causes a more severe TMD phenotype (Study II). The 
patient had several rare missense variants in the TTN A-band region, and 
likely some of them contribute to the phenotype, but their significance could 
not be determined. Patient P20 with upper limb muscle weakness had a 
splice site mutation c.107377+2->T in TTN intron 361, which introduced a 
new splice site and resulted in a transcript with an extra G between exons 361 
and 362 leading to a frameshift and three exchanged amino acids before the 
stop codon. The mutation was also present in the patient’s healthy sister and 
thus not likely to have a dominant effect. The possible other TTN mutation 
could not be determined. Patient P21 with proximal muscle weakness 
starting before the age of 30 had a TTN mutation c.106531 + 2T>A that 
caused skipping of exon 359 (Mex2), but which was not likely to cause the 
disease alone, since the patient’s son also had the mutation and was healthy 
at age 37. The possible other TTN mutation could not be determined. 
 
5.1.4 MUTATIONS IDENTIFIED IN THE RECESSIVE DISTAL 
TITINOPATHY PATIENTS (IV) 
Six distal myopathy families with recessive inheritance pattern were included 
in this study. Family A was from Albania with the proband living in Italy. The 
proband had a distal muscle weakness in the lower limbs starting at age 36. 
Family B was from Bosnia and had two affected members. The proband had 
atrophy and weakness of tibialis anterior muscles in the lower leg with 
disease onset at 25 years. Her brother had weakness of toe and foot extensors 
and walking difficulties since childhood. On examination he was 32 years old 
and he had been diagnosed with cardiomyopathy years before after an 
episode of acute tonsillitis and myocarditis. Family C was from Iran and the 
proband had weakness of lower limb muscles and walking difficulties since 
the age of 29. Family D was from Tunisia and the proband had progressive 
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distal and proximal muscle weakness in the lower limbs starting at age 24. 
Her sister (P9 from Study III) had similar phenotype and the same disease 
onset. Family F was from Spain and the proband (P8 from Study III) had 
distal and proximal lower limb muscle weakness starting at age 4. His 
brother had similar muscle weakness, but with disease onset in the teens. 
Family G was from Spain and the proband (P14 from Study III) had a novel 
phenotype with severe weakness in tibialis anterior muscles and mild muscle 
weakness in wrists, fingers, shoulders and hips. 
 
One affected patient from each family was screened for mutations using the 
MyoCap gene panel. Recessive TTN mutations in either homozygous state or 
in compound heterozygosity with a nonsense or frameshift mutation were 
identified in the patients (Table 8). Family members carrying only one of the 
identified mutations were healthy. 
 
Table 8. Identified TTN mutations in the recessive distal titinopathy patients 
(NM_001267550.1 and NP_001254479.1). 
Family Ethnicity Exon DNA Protein 



































Altogether three novel TTN mutations in exons 362 (Mex5), 363 (Mex6) and 
340 (A-band) were identified and the previously reported Iberian TMD 
mutation in one family. The mutations were in compound heterozygosity 
with I- or A-band nonsense or frameshift mutations. The phenotypes 
observed in the patients with novel Mex5 or Mex6 mutations and truncating 
mutations were similar to the phenotypes seen in the patients in Study II. It 
is possible that these novel Mex6 mutations also cause a dominant late onset 
mild TMD phenotype like the previously reported dominant Mex6 TMD 
mutations. Three of the families (A, B and C) shared the same mutation 
(c.107635C>T, p.Q35879*) in Mex5. Genotyping using eight microsatellite 
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markers around TTN was performed and the affected members in the 
families also shared the same haplotype, suggesting a common origin of the 
mutation. The families are of different ethnicity, Albanian, Bosnian and 
Iranian, and it is likely that more families with this mutation exist, but the 
mutation manifests the disease only when in compound heterozygosity with 
a truncating TTN mutation. 
 
RT-PCR from muscle biopsies of patients from families B and C was 
performed and it suggested unequal expression of the TTN alleles in the 
patients showing lower signals from the I- and A-band nonsense mutations 
compared to the Mex5 mutated allele. The results were similar as in the 
previous TMD complex patients (Study II). The lower expression of the I- 
and A-band nonsense alleles is likely due to NMD as the mutations cause a 
premature stop codon in the sequence >50-55 nucleotides upstream of the 
last exon-exon junction (Nagy and Maquat, 1998). Western blotting using 
antibody for M10 domain was also performed on a patient from family C and 
it showed reduction of titin fragments, but not complete absence of the 
protein as seen in the LGMD2J biopsy. The detected protein very likely 
originated from the normal is7- isoform, which lack the is7 domain and also 
the mutation. 
 
All the identified I- and A-band nonsense and frameshift mutations seem to 
be recessive as the heterozygous carriers of the mutations were healthy at age 
53-65. Dominant cardiomyopathy has been observed in patients with 
truncating mutations in TTN A-band (Herman et al., 2012). Cardiomyopathy 
was present in one of the Bosnian patients, but it was likely caused by 
something else than the truncating TTN mutation, since the patient's sister 
with the same combination of TTN mutations did not have cardiomyopathy, 
as well as their father who was a healthy heterozygous carrier of the 
truncating A-band mutation. 
 
Distal myopathy -causing mutations in the TTN A-band region have not been 
previously reported. In this study, a patient in the family G had a novel 
missense mutation c.94285T>A (p.W31429R) in TTN exon 340 in compound 
heterozygosity with a nonsense mutation c.63625C>T (p.R21209*) in exon 
306. Segregation of the mutations was studied in the family members. Only 
the affected had both of the mutations, whereas the healthy mother and 
brother carried the missense A-band mutation and the healthy father and 
sister carried the nonsense A-band mutation, indicating that the mutations 
are recessive and in different TTN alleles. The missense mutation causes an 
exchange of a conserved hydrophobic tryptophan to a positively charged 
arginine. The tryptophan is buried in the FN3 domain and the exchange most 
probably breaks the hydrophobic core of the domain and leads to an 
unfolded FN3. The mutation presumably causes the disease by a loss-of-
function mechanism when interactions of the domain are disrupted. Two 
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putative ligands for the domain are dysferlin and angiomotin (Blandin et al., 
2013), but their interaction with titin requires confirmation. The patient had 
a novel distal myopathy phenotype with severe weakness in tibialis anterior 
muscles and milder muscle weakness in wrists, fingers, shoulders and hips. 
5.2 MYOCAP GENE PANEL (III) 
The MyoCap gene panel was developed in order to enhance genetic testing in 
primary myopathies. Previously the main method to detect mutations was 
Sanger sequencing of single candidate genes. This was a slow and laborious 
method especially for patients with less distinct phenotypes when several 
genes needed to be sequenced in order to identify the causative mutation or 
for patients with huge candidate genes. Targeted gene panels provide fast 
and cost-efficient solution to sequence several genes simultaneously and with 
better coverage compared to WES. 
 
A total of 138 previously reported myopathy-causing genes (Kaplan and 
Hamroun, 2012) and 42 novel genes were selected to the panel. The novel 
genes were not previously reported to cause myopathy, but were considered 
interesting, since they encode proteins that have direct interactions with 
known myopathy associated proteins. Probes were designed for the coding 
exons and UTRs of the gene transcripts present in databases RefSeq, 
Ensembl, CCDS, Gencode and VEGA. The total size of the target region was 
1.3 Mb and contained 3999 exons. SeqCap EZ Choice Library from 
NimebleGen was chosen as capture kit since the NimebleGen SeqCap EZ 
enrichment system was reported to have more specific targeting and 
enrichment characteristics with more high quality reads, deeply covered base 
pairs and a more uniform coverage in the target regions compared to Agilent 
SureSelect enrichment system (Sulonen et al., 2011). 
 
The first MyoCap screen was performed on selected myopathy patients 
without molecular diagnosis despite of extensive candidate gene approaches. 
Altogether 61 patients were selected, and four additional patients having 
previously identified mutations served as mutation controls. The patients 
were from 15 different countries and had different myopathies, the most 
common phenotypes being distal myopathy and LGMD. The mode of 
inheritance was dominant in 14 patients, recessive in 15 patients and 32 
patients were sporadic. 
 
5.2.1 COVERAGE IN THE TARGET REGION 
The mean read depth in the target region was 131X, and on average 94.8% of 
the target region was covered with at least 20X. The reads did not cover the 
target region uniformly, because some regions were more difficult to 
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sequence than others. The poorly covered 5.2% of the target region 
comprised mainly repetitive or GC-rich regions. Overall 147 exons of the total 
3999 target exons had read depth less than 20X in all analyzed samples and 
44 exons had no reads at all. Problems with repetitive and GC-rich sequences 
have been encountered in other targeted gene panels as well (Vasli et al., 
2012; Valencia et al., 2012). GC-rich sequences contain more than 60% of 
guanine and cytosine nucleotides. These regions are very stable because of 
stacking interactions and secondary structures, for example hairpin loops, 
causing problems in the PCR amplification step. By optimizing the PCR 
conditions the coverage in the GC-rich regions could probably be increased 
(Aird et al., 2011). The 32 kb triplicate region in NEB and the 10 kb triplicate 
region in TTN were poorly covered due to high degree of repetitiveness. 
Longer read lengths could help to overcome the aligning problem of 
repetitive sequences (Li and Freudenberg, 2014). The average read depth 
also varied between the samples ranging from 26X to 238X and was likely 
caused by pooling of the samples and differences in the DNA concentrations. 
 
5.2.2 SPECIFICITY OF THE ASSAY 
All the seven mutations in the four control patients were detected. The 
mutations included a single-nucleotide substitution, a single nucleotide-
duplication, a four-nucleotide duplication, three single-nucleotide deletions 
and an eleven nucleotides insertion/deletion mutation (FINmaj), which was 
shown as four different mutations in the results: a deletion, an insertion and 
two substitutions. According to this relatively small sample set MyoCap 
seemed to be a reliable method to detect small substitutions and indels. 
CNVs and SVs were not analyzed, because their detection is rather inaccurate 
due to non-uniform coverage and noncontiguous nature of the targeted 
regions (Benjamini and Speed, 2012). 
 
The average amount of variants detected per patient was 1589. After filtering 
out variants having frequency >1% in 1000 Genomes and ESP6500 an 
average of 35 variants were left in the results, including variants in the coding 
exons and intronic variants that were located less than 15 bp from exon-
intron borders. Intronic variants close to exons were included in the results 
in order to detect variants possibly affecting splicing. The vast majority of the 
detected variants were real. Sanger sequencing of 85 variants confirmed 82 
of them to be true positives, providing the specificity value of 96%. 
 
Detection of indels is more challenging than detection of substitution 
mutations, because reads overlapping the indel sequences are more difficult 
to map (Li et al., 2008). Often the number of detected substitutions is very 
similar when comparing different NGS platforms or analysis tools, but the 
number of indels can differ greatly (Jiang et al., 2015). This was also seen in 
the MyoCap data, in which two variant calling algorithms, GATK and 
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SAMtools, were used. GATK called only slightly more SNVs (84 327 vs. 83 
647), but notable more indels (11 350 vs. 7692) than SAMtools. It is possible 
that GATK has a higher false positive rate, but in turn SAMtools missed three 
pathogenic single-nucleotide deletions in the patients, which were detected 
by GATK and then confirmed by Sanger sequencing. According to these 
results GATK seems to be more reliable than SAMtools in indel detection. 
The majority of the SNVs (83 316) and indels (6766) were called by both 
algorithms. 
 
5.2.3 MYOCAP COMPARED TO OTHER TARGETED GENE PANELS 
AND WES 
Several targeted gene panels for myopathies and other neuromuscular 
disorders have been reported (Table 9). Two of the reported gene panels 
contained genes for all known neuromuscular disorders. MyoCap was 
decided to contain only genes for myopathies to reduce unnecessary 
sequencing, because myopathic and neuropathic weakness can be 
distinguished, e.g. using electrodiagnostic testing (Paganoni and Amato, 
2013) and another gene panel for neuropathies was designed. Myopathies 
can have overlapping phenotypes and thus all myopathy related genes were 
included in the same panel instead of dividing them into smaller subgroups. 
In addition, 42 new genes were included, but it did not lead to identification 
of pathogenic mutations in them in the first MyoCap screen. Chae et al. had 
also selected over 200 new genes into their panel, but did not report any 




Table 9. The characteristics of different neuromuscular gene panels. 
















































































































































































































Different enrichment systems and sequencing platforms were used in the 
gene panels with Agilent HaloPlex and Illumina HiSeq being the most 
popular. Almost all panels resulted in high coverage and sensitivity with 
exception being the RainDance micro-droplet-based PCR and SOLiD 
platform used in the panel of Valencia et al. MyoCap performed well 
compared to others, but the percentage of bases having more than 20X reads 
could likely be increased by increasing the sequencing depth. It is important 
to determine the sufficient sequencing depth to ensure adequate coverage 
and reliable mutation detection, but not to waste money on excess 
sequencing. The sensitivity and specificity were high in the reported gene 
panels and all the control mutations were detected, except in the panel of 
Valencia et al. with several mutations missed. The false positive rate was 
lowest in MyoCap and MotorPlex. 
 
Previously a comparison of in-solution hybridization based (NimbleGen 
SeqCap EZ and Agilent SureSelect) and amplicon based (Agilent HaloPlex) 
enrichment systems has been published (Samorodnitsky et al., 2015). The 
report noted that HaloPlex requires less experimental time and lower DNA 
input than SureSelect and SeqCap, but the disadvantage of the HaloPlex 
system is that it uses restriction enzyme digestion that leads to low library 
complexity, high duplicate rate and in case SNVs occurring in or near digest 
sites it may limit capture. The SeqCap and SureSelect enrichment systems 
use sonication for fragmentation and show high complexity in libraries, 
which lead to higher uniformity of coverage and more evenly distributed 
performance also in the GC-rich and GC-low regions (Samorodnitsky et al., 
2015). This can be seen as an advantage in MyoCap, which uses SeqCap 
enrichment system. 
 
Diagnostic yields of different panels were difficult to compare, because many 
of the variants were reported to be possibly pathogenic or of unknown 
significance. In majority of the gene panel screens, including MyoCap, less 
than half of the patients received a definite molecular diagnosis. The 
unsolved patients likely have the causative mutation outside the panel genes. 
It is also possible that some patients may have the causative mutation in 
more than one gene resulting in new phenotypes, which can make the 
interpretation of the results difficult, and lead to missed diagnosis. A few 
patients having recessive disorders, but only one pathogenic mutation 
compatible with the phenotype identified, were also found. It is possible that 
the other mutation was in some of the low coverage regions, or it could have 
been a deep intronic mutation or CNV, which were not analyzed in MyoCap. 
 
MyoCap was also compared to WES, which was performed on 27 research 
patients using NimbleGen SeqCap EZ Human Exome v2.0. MyoCap had 
higher read depth (139X vs. 44X) and coverage (94.0% vs. 65.0% > 20 X) in 
the MyoCap coding regions providing better sensitivity and specificity. 
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MyoCap is also more suitable for diagnostics than WES, because it is many 
times cheaper and contains only the most relevant myopathy causing genes 
generating less data and requiring less storage space. Many diagnostics 
patients have mutations in the known myopathy genes and sequencing more 
genes is useless. MyoCap can also be easily updated when new discoveries of 
disease genes are made. 
 
5.2.4 IDENTIFIED MUTATIONS IN OTHER GENES THAN TTN 
Altogether 61 research patients negative for previous candidate gene 
approaches were sequenced in the first MyoCap screen. The causative 
mutation was solved in nine patients. Three patients had previously reported 
mutations, but a phenotype that had not previously been associated with the 
mutation. Four patients had probable causative mutations, but more 
evidence is still needed to confirm their pathogenicity. Three recessive 
patients had one likely pathogenic mutation, but the other causative 
mutation could not be determined. 42 patients remained unsolved. The 
genetic defect was thus totally or partly clarified in 19/61 patients (31%). The 
result was reasonable good considering that the patients were already 
extensively studied and the majority of candidate genes had been excluded. 
The identified mutations in TTN were described in the previous chapters and 
the mutations in other genes are described here. 
 
Patients P1-P6 were identified to have previously reported mutations with 
compatible phenotypes. The findings are listed in Table 10. A majority of 
these patients had either distal myopathy or LGMD, which can be 
challenging disorders in molecular diagnostics when using Sanger 
sequencing as the number of possible candidate genes is high. This was also 
the reason why the mutations had not been detected earlier in the patients. 
Patient P7 with an LGMD phenotype had a novel 15-bp in-frame deletion in 
FLNC, in the same location as previously reported 12-bp in-frame deletion 
causing myofibrillar myopathy (Shatunov et al., 2009). Clinical overlap of 
myofibrillar myopathy and LGMD has been demonstrated (Vorgerd et al., 
2005) and it was a plausible explanation also for this patient. The mutation 





Table 10. Identified mutations in other genes than TTN in the MyoCap screen. AD = 
autosomal dominant, AR = autosomal recessive, XD = X-linked dominant, S = sporadic. 
Patient 
Origin 










p.D109H reported S 
Distal 
myopathy 
P3        
UK 
FHL1:NM_001449:exon5:c.458G>A: 




P4     
Finland 
FKRP:NM_024301:exon4:c.826C>A: 
p.L276I (homozygote) reported AR LGMD 
P5  
Germany VCP:NM_007126:exon3:c.277C>T:p.R93C reported S 
Distal 
myopathy 
P6     
Greece 
GNE:NM_001128227:exon10:c.1853T>C: 







2800del:p.V930-A934del novel AD LGMD 
P10    
France 
MYH7:NM_000257:exon37:c.5329G>A: 
p.A1777T reported S 
Distal and axial 
myopathy 



























Patient P10 had a previously reported missense mutation c.5329G>A 
(p.A1777T) in MYH7 exon 37. The mutation has been reported to cause 
hypertrophic cardiomyopathy (Richard et al., 2003), but the patient had 
distal and axial myopathy. MYH7 encodes β-myosin heavy chain, found in 
cardiac muscle and type 1 skeletal muscle fibers. Mutations in the gene cause 
both cardiac and skeletal muscle diseases (Colegrave and Peckham, 2014). 
Mutations in exons 32, 34, 35, and 36, have been reported to cause distal 
myopathy (Meredith et al., 2004) and this mutation was considered to be the 
likely cause of the disease. 
 
Patients P11 and P12 had previously reported SQSTM1 mutations, but 
atypical phenotypes, not previously associated with the mutations. Patient 
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P11 with distal myopathy had a missense mutation c.1175C>T (p.P392L) in 
exon 8 and patient P12 with scapuloperoneal myopathy had a splice site 
mutation c.1165+1G>A in intron 7. The mutations have been reported to 
cause Paget’s disease of bone and amyotrophic lateral sclerosis (ALS) when 
heterozygous (Laurin et al., 2002; Hocking et al., 2002; Fecto et al., 2011; 
Teyssou et al., 2013), but the patients did not have these disorders. SQSTM1 
is an autophagic adaptor protein that shuttles aggregated and ubiquitinated 
proteins to the autophagosome for degradation via its C-terminal ubiquitin-
associated (UBA) domain. The SQSTM1 c.1165+1 G>A mutation results in the 
expression of two alternatively spliced SQSTM1 proteins: one lacking the C-
terminal PEST2 domain and another lacking the C-terminal UBA domain 
(Bucelli et al., 2015). P12 is the sporadic patient in Bucelli et al. The article 
also described two brothers from US having the same mutation and a distal 
myopathy phenotype. The patients P11 and P12 had, in addition to the 
SQSTM1 mutation, a rare TIA1 variant c.1070A>G (p.N357S) (0.7 % allele 
frequency in ExAC), which was located in the same exon as the previously 
reported pathogenic TIA1 mutation c.G1150A (p.E384K) causing Welander 
distal myopathy (Klar et al., 2013; Hackman et al., 2013). TIA1 encodes a 
cytotoxic granule-associated RNA binding protein (TIA1), which is involved 
in splicing regulation and translational repression (Del Gatto-Konczak et al., 
2000; Piecyk et al., 2000). TIA1 is a key component of stress granules, which 
are cytoplasmic foci that sequester untranslated mRNAs during different 
types of cellular stress (Kedersha et al., 1999; Kedersha et al., 2000; Gilks et 
al., 2004). Subsequent MyoCap runs have revealed more distal myopathy 
patients having combination of reported SQSTM1 mutation and the TIA1 
p.N357S variant. The TIA1 variant is suggested to have an effect to the 
phenotype on the patients, but more studies are needed to confirm this. 
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6 CONCLUSIONS AND FUTURE PROSPECTS 
This doctoral thesis describes novel pathogenic mutations and previously 
reported mutations associated with novel phenotypes in muscular dystrophy 
patients. Sanger sequencing, WES and a custom made targeted gene panel, 
MyoCap, were used to detect the mutations in the patients. As a result, more 
than 30 families or sporadic patients obtained a molecular diagnosis. The 
majority of the mutations were identified in TTN, which encodes the 
enormous sarcomeric protein titin. The gene comprises 363 exons, and due 
to its huge size, it was not routinely sequenced in diagnostic efforts before the 
NGS era, and novel findings in it were expected. 
 
WES was performed on one French family having HMERF and a novel 
missense mutation in TTN exon 343 was identified. During the same time 
HMERF mutations in the same exon were reported in three British and three 
Swedish families (Ohlsson et al., 2012; Pfeffer et al., 2012). This led to the 
identification of several other HMERF mutations when the exon was Sanger 
sequenced from the rest of the families. Altogether five different TTN 
missense mutations in 12 unrelated HMERF families were identified in this 
study. The families were from Finland, France, Britain, Sweden, Italy, 
Germany and Argentina. The results considerably expanded the mutational 
spectrum of HMERF and highlighted the geographically wide occurrence of 
the disease as well as the role of TTN exon 343 as a mutational hotspot 
region. Four of the identified mutations showed dominant inheritance, but 
one seemed to be recessive, since it did not always cause a disease in the 
heterozygous state. Further studies are needed to clarify why some 
heterozygous patients manifest a disease, while some do not. One 
explanation could be an additional mutation in TTN or in some other gene. 
Another unsolved issue is why mutations in this exon and not in other exons 
coding similar FN3 domains of A-band titin cause HMERF disease with the 
very unique pattern of muscle involvement. Since this pattern and the 
pathology is identical with HMERF caused by the combination of the 
recessive mutation and the mutation in the kinase domain of titin on the 
same allele in some families, a regulatory function of autophagy turnover by 
the corresponding FN3 domain is possible. 
 
Six patients having heterozygous TMD mutation, but more severe or atypical 
phenotype were identified to have an additional mutation in the other allele 
of TTN. In a majority of these patients the mutation was a truncating 
mutation in the I- or A-band region. The phenotype of the patients was very 
similar to the phenotype of homozygous patients with the corresponding 
TMD mutation. However, phenotype differences between compound 
heterozygous patients with different Mex5 or Mex6 mutations were observed. 
The Finnish patients with the FINmaj TMD mutation in compound 
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heterozygosity had an LGMD phenotype, while patients with the French 
Mex5 or Iberian TMD mutation in compound heterozygosity had a more 
severe distal phenotype with earlier onset and more rapid progression 
compared to TMD. Previous studies showing that the FINmaj mutation 
disrupts a more crucial region in the M10 domain (Fukuzawa et al., 2008) 
and the fact that it leads to an absence of a larger part of the titin C-terminus 
(Hackman et al., 2002; Charton et al., 2015) could explain the differences 
seen in the phenotypes. One patient having the FINmaj mutation had also in 
compound heterozygosity a novel missense mutation in TTN exon 339 and a 
novel adult-onset phenotype with weakness in calf and thigh muscles 
differing from both TMD and LGMD2J. The results suggest that coexistence 
of two TTN mutations in patients may be a more common mechanism 
causing phenotypic variability in titinopathies. 
 
The MyoCap gene panel was used to detect mutations in six families with 
juveline or early adult onset recessive distal titinopathy. The patients had a 
mutation in Mex5, Mex6 or A-band exon 340 in compound heterozygosity 
with an I- or A-band truncating mutation. The patients with the novel Mex5 
or Mex6 mutations had similar more severe TMD phenotype as the patients 
having the previously reported French Mex5 or Iberian Mex6 TMD mutation 
in compound heterozygosity with a truncating mutation. The missense 
mutation in the A-band was the first distal myopathy causing mutation 
identified in the titin A-band region. The results expanded the list of distal 
myopathies with a new category: juvenile or early adult onset recessive distal 
titinopathy. 
 
Several truncating mutations mainly in the titin I- and A-band regions were 
identified in this study. The truncating mutations seem to be harmless in 
heterozygosity, but can cause variable phenotypes in compound 
heterozygosity with other TTN mutations. The RT-PCR results suggested that 
the nonsense and frameshift mutations located upstream of the last exons of 
TTN likely cause NMD, while the nonsense and frameshift mutations located 
in the last two exons do not. This is in agreement with the observation that 
NMD occurs when the premature stop codon is located >50-55 nucleotides 
upstream of the last exon-exon junction (Nagy and Maquat, 1998). 
Quantitative PCR would be needed to confirm these findings. NMD is often 
incomplete, but the amount of expressed truncated titin proteins in these 
patients is not known. Further studies using Western blotting with an 
antibody that detects truncated titins would give some insight to this. 
Truncating mutations in titin A-band have been reported to cause dominant 
cardiomyopathies, but it was not the case in the patients of this study. Only 
one of the patients had cardiomyopathy and it was likely due to something 
else than TTN mutations, since the patient’s sister with the same 
combination of TTN mutations did not have any cardiomyopathy. The reason 
why some frameshift and nonsense mutations in the TTN A-band region 
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cause cardiomyopathy and some do not is still to be clarified. The prevalence 
of truncating TTN A-band variants is 0.19 % in the ExAC database suggesting 
that 1 in 500 individual carries a truncating TTN A-band variant (Akinrinade 
et al., 2015). The truncating I- and A-band TTN mutations identified in this 
study seem to be recessive and harmless in heterozygosity, but in compound 
heterozygosity with other TTN mutation they cause various titinopathy 
phenotypes depending on the other mutation. 
 
Several missense mutations in TTN were also identified in this study. The 
pathogenicity of a missense mutation is often difficult to determine and more 
studies are needed to elucidate the effects on the protein level. Further 
studies could include computational modelling and in silico analyses, 
expressing of titin domains and characterizing their biochemical properties, 
and interaction studies of titin and its ligands. Sequencing of large genes, like 
TTN, is not a problem anymore, the biggest challenge now is in the 
interpretation of the results. How to determine which variants are 
pathogenic as almost every individual carries rare TTN variants. Additional 
patients with similar phenotype and genotype characteristics could give some 
insight to this. One possible approach to address this could be to collect and 
combine phenotype and genotype data from different laboratories more 
systematically. 
 
During the last years NGS methods have proven to be accurate and highly 
efficient methods to detect pathogenic mutations. They are also cheaper, 
faster and less laborious than the conventional Sanger sequencing. The 
MyoCap gene panel was designed to detect mutations in primary myopathies. 
It has been implemented in the routine molecular genetic diagnostics of 
myopathy patients and it has accelerated the detection of mutations 
remarkably. NGS gene panels overcome the diagnostic challenges of 
numerous or large candidate genes and patients with atypical phenotypes 
can also get their molecular genetic diagnosis. MyoCap has been updated 
twice and the current third version contains 265 genes. MyoCap is now the 
first method of choice for detecting mutations in diagnostic patients in 
Finland if no clear candidate gene can be determined. WES or WGS is still 
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